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ABSTRACT 
Richard L Watkins: Role of HIV-1 Nef and Vpu in viral replication and CD4+ T cell depletion. 
(Under the direction of J Victor Garcia-Martinez)  
 
  HIV-1, within its 9-gene genome, encodes a set of accessory proteins regarded as non-
essential for in vitro replication, but that are critical for optimal viral replication in vivo. 
Specifically, Nef and Vpu, two proteins with some overlap in function, have been implicated in 
robust viral replication and disease progression. 
  As part of my dissertation I used an LAI with a simple frame-shift in nef, ablating the 
expression of Nef, and demonstrated the in vivo pressure to restore the nef ORF. I went on to 
show, that the protein resulting from the reopening of the nef ORF was defective for CD4 
downmodulation.  Mice infected with LAI containing these in vivo generated nefs displayed 
reduced viral loads and the CD4 depletion compared to mice infected with wild type LAI. When 
the infections with a more severally defective nef that was irreversibly inactivated are compared 
to infections with LAI containing Nefs defective for CD4 downmodulation, I found that nearly 
50% of the pathogenic phenotype of wild type LAI could be attributed to Nef’s ability to 
downmodulate surface expression of CD4.  
 iv 
  I also examined the role that Vpu plays in replication and CD4+ T cell depletion during 
an LAI infection in BLT-humanized mice. These investigations demonstrate that Vpu is required 
for rapid CD4+ T cell depletion and high viral loads. Of interest is that Vpu-defective HIV-1 
expressing no Vpu and HIV-1 expressing Nef specifically lacking the ability to downmodulate 
CD4 have strikingly similar replicative and pathogenic phenotypes. 
  I also examined the contribution nef makes to high viral loads and CD4+ T cell depletion 
during the infection of the CCR5-tropic virus, HIV-1 JRCSF. Mice infected with JRCSF 
expressing defective nefs have lower viral loads and maintain a higher percentage of their CD4+ 
T cells than mice infected with wild type JRCSF. I also demonstrate that like LAI, JRCSF 
expressing a frame-shifted nef restores the nef ORF. I show in this dissertation that the Nef 
produced by one of these in vivo-generated nef mutants is also specifically defective for CD4 
downregulation. I also performed a longitudinal analysis of peripheral blood CD8+ T cell 
activation to demonstrate that Nef is required for increased T cell activation during JRCSF 
infection.   
My dissertation demonstrates that the high viral loads and CD4+ T cell depletion seen 
during HIV infection depends on the presence of Nef and Vpu.  Specifically, Nef has a critical 
role in determining the outcome of infection.  The presence of Nef is required for immune 
activation, which may explain differences in pathogenic outcomes.   
 v 
 
 
“If you don’t fall from your bike once in a while you’re not going fast enough.” 
-Richard L Watkins Jr. 
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CHAPTER 1: INTRODUCTION 
1.1 The evolution of the AIDS pandemic   
  If untreated, Human Immunodeficiency Virus (HIV) infection leads to the near total 
depletion of CD4+ T cells [1-3]. The consequence of this depletion is that the infected individual 
is left with a crippled immune system and is vulnerable to opportunistic infections and, 
consequently, the subsequent development of Acquired Immune Deficiency Syndrome (AIDS) 
[3-6]. AIDS, according to the World Health Organization (WHO), has claimed the lives of 35.9 
million, making it one of the worst public health concerns in modern human history [7].  
The pandemic that is AIDS is caused by HIV-1, which is the consequence of the cross-
species transmission of simian immunodeficiency viruses (SIVcpz) from chimpanzees to humans 
[8-10].  SIVcpz spawned from transmission and recombination events involving at least two 
separate lineages of SIV, an SIV strain from red-capped mangabeys (SIVrcm) and from 
Cercopithecus monkeys [11]. SIVcpz strains were transmitted into humans on at least three 
occasions, one of which resulted in the cross-species transmission of the precursor of HIV-1 
group M (major) [8]. Other episodes resulted in the cross-species transmission of the precursor 
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of HIV-1 group O and the rare HIV-1 group N [12]. HIV-1 group M strains have accounted for 
the infection nearly 60 million people [9, 13].  
After entry into humans, HIV-1 group M has diverged into multiple subtypes (A, B, C, D, 
F, G, H, J, and K) and over 50 recombinant forms [14, 15]. Despite the high degree of 
divergence in HIV-1, the lentiviruses found in chimpanzees are even more diverse [16].  
Underlying this diversity is the fact that humans and chimpanzees all have the same gene 
structure; in 5’ to 3’ order they are gag, pol, vif, vpr, tat, rev, vpu, env, and nef.  Monkey viruses 
exhibit differences in gene structure from the chimpanzee/human lentivirus, which are gag, pol, 
vif, vpx/vpr, tat, rev, env, and nef [8, 12].  The non-primate lentivirus feline immunodeficiency 
virus (FIV) is closely related to HIV-1 [17, 18]; the genes in FIV are gag, pol, vif, orfA, rev, and 
env.  orfA has multiple functions reminiscent of those of vpr, tat, and nef [18]. Viral tropisms in 
the case of feline and primate viruses are similar in that both types are able to infect T cells and 
cells of monocytic lineage [17, 19-21]. The T lymphocytic tropism of FIV derives from using 
CD134 as its primary receptor [19].  Both HIV and FIV viruses also have a co-receptor, CXCR4 
[22].  However, HIV-1 uses CD4 as the primary receptor and CCR5 as the co-receptor [23, 24].  
Late in infection, virus can emerge that uses CXCR4 as co-receptor [4, 25].  Interestingly, the 
orfA-encoded protein downregulates its primary receptor, CD134, from the cell surface 
analogous to the downregulation of CD4 by Nef [26, 27].  
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In humans, HIV-1 infects CD4+ T cells via receptor- and co-receptor-mediated 
adsorption. Once inside the cell, HIV-1 uncoats and then reverse transcribes its RNA-based viral 
genome into a provirus [28, 29].  The provirus is permanently integrated into the host genome 
where host factors produce viral transcripts, splice the transcript into multiple mRNAs, and 
translate viral proteins.  The nascent virion buds from the cell membrane and coats the virus in a 
lipid layer. Upon viral release, immature virions are converted into mature infectious virions by 
the viral protease [30-32], a process that  leads to the production of thousands of progeny virions 
and provides several steps that innate host cell defenses can attack [33, 34]. However, while the 
defenses of the human host may have been sufficient at stopping retroviral infections in our 
ancestors, our current defense repertoire against HIV-1 is insufficient.      
The susceptibility of the host to viral infections and the likelihood of cross-species 
transmission depend heavily on the ability of the virus to evade different host mechanisms of the 
host immune system [35]. These restriction factors limit progression at various stages of the viral 
lifecycle; for example, APOBEC3G (A3G), TRIM5α, and tetherin [8, 34], whose functions are 
the 1) creation of lethal hypermutations, 2) untimely uncoating of reverse transcription 
complexes, and 3) inhibition of viral release from infected cells, respectively [34].  HIV-1 has 
mechanisms to antagonize every host cell restriction factor.  
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HIV-1 reverse transcriptase makes an error in transcribing RNA to DNA approximately 
once in every 10,000 nucleotides [36]. In addition, HIV-1 is also highly recombinogenic [8, 37-
39]. In HIV-1 infected individuals, billions of progeny viruses are produced each day [40, 41]. 
The viral generation of HIV-1 is 1.2 days [42]; thus, the potential for variation among HIV-1 
quasispecies within an infected individual is great.  HIV-1 evolves rapidly to counter various 
aspects of the host’s immune system [8]. Although HIV-1 contains just nine genes, four (vif, vpr, 
vpu, and nef) are used to avoid and antagonize host cell factors that limit viral replication [8]. 
The activity of accessory proteins has been viewed as dispensable, due to the lack of observable 
effects on in vitro replication upon their ablation [8, 43]. However, these accessory proteins are 
strongly conserved in regards to natural infection, demonstrating their importance [44]. In fact, 
the presence of these accessory genes has allowed the successful cross-species transmission of 
SIV that resulted in the virus that created the HIV-1/AIDS pandemic [8, 45]. 
1.1.2 Human and HIV-1 ancestors 
Primates originated from an ancestor that lived in the trees of tropical forests; many 
primate characteristics represent adaptations to life’s challenges, which include both 
environmental and viral factors [44, 46]. For example, most primate species remain at least 
partly arboreal [47]. On the other hand, examples of adaptations to viral challenges can be seen 
in the arsenal that the primate host welds against viral infection, specifically to SIV and HIV. 
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HIV and SIV are members of a family of viruses known as retroviruses, whose ancestral fossils 
can be found littered throughout the genomes of primates, both human and non-human; these 
genomic relics are known collectively as endogenous retrovirus (ERVs). Implicit in each ERV is 
the victory over a retroviral infection by the host immune system, specifically factors of the 
immune system intrinsic to the host cell. The host cell possesses measures to effectively thwart 
viral infection at multiple steps in the viral life cycle. 
HIV-1 belongs to the genus of lentiviruses. Many lentiviruses exist; one of the  oldest is 
rabbit endogenous lentivirus type K (RELIK) [8, 48]. RELIK, like HIV-1, contains the structural 
and regulatory genetic elements gag, pol, env, tat, and rev but, unlike HIV-1, lacks homologs of 
the genes vif, vpr, vpu, and nef [8], genes that were acquired over the course of 12 million years 
in which RELIK-like lentiviruses jumped from species to species. The absence of homologs 
suggests that vif, vpr, vpu, and nef gave the predecessors to HIV-1 a selective advantage over 
their evolutionarily forgotten peers. For example, the younger (~ 2 million years) endogenous 
lentivirus, the gray mouse lemur prosimian immunodeficiency virus (pSIVgml) from a 
Madagascan lemur, contains a vif gene [8]. With vif, lentiviruses were able to counter the anti-
viral function of the APOBEC3 genes that have deep roots in mammalian evolution [8]. From 
here the prosimian virus, pSIVgml, could serve as the precursor to a virus capable of 
transmission into simians, which would require acquiring the genes vpx, vpr, and nef. Although 
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the acquisition of the genes vpr and nef allowed for transmission into simian hosts, the 
acquisition of these genes was insufficient for transmission into chimpanzees, an event that 
would require the acquisition of yet another gene, vpu.  
Vpu is an 81 amino acid type I membrane protein and functions to decrease the surface 
expression of both tetherin and CD4 [34, 49].  Tetherin, a crucial hurdle in the cross-species 
transmission of SIV, is also antagonized by Nef. The antagonism of tetherin by both vpu and nef 
is a result of the co-evolution of SIV with its respective primate host, as not all SIVs contain the 
vpu gene. In fact, it was a recombination event within an infected chimpanzee that introduced 
vpu into what is now HIV-1 [45].  vpu is believed to have been introduced into chimpanzee SIV 
(SIVcpz) via the recombination of an ancestor to an SIV found in cercopithecus monkeys 
(SIVsun) and SIV in the red-capped mangabey (SIVrcm) [8, 12, 50]. The recombined SIVcpz 
spread in chimpanzees and later transmitted to both gorillas and humans to create what is now 
SIVgor and HIV-1 [8].  
 The antagonism of tetherin by HIV-1 Vpu represents the co-evolution of primate 
lentiviruses with their host, with the host evolving to thwart the viruses of its ancestors only to 
later succumb to the descendants of those very same viruses [8]. Specifically, mammalian cells 
evolved restriction factors to protect themselves from lentiviruses among other viruses; however, 
lentiviruses specifically have accessory proteins to overcome these restriction factors [34, 44].  
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Moreover, the countering of these restriction factors has allowed HIV-1 to become one of the 
worst pandemics in human history [8].    
1.2 Tetherin and CD4 
 Bone marrow stromal antigen 2 (BST2) or tetherin, is a lipid raft-associated innate 
restriction factor [51].  Tetherin  is not constitutively expressed, but is interferon-dependent and 
prevents virion release from the cell surface of the infected cell [52, 53]. Tetherin antagonism by 
Vpu has been shown to decrease the susceptibility of HIV-infected cells to antibody-dependent 
cell mediated cytotoxicity [54]. Another investigation showed that in the absence of Vpu, natural 
killer (NK) cell-activating FcgRIIIa signaling and NK cell degranulation and NK cell-mediated 
antibody-dependent-cell-mediated-cytotoxicity were enhanced, although the mechanism of this 
effect is unknown [55]. The second major role of Vpu is downregulating CD4. Vpu prevents 
newly translated CD4 from being expressed on the cell surface via endoplasmic reticulum 
associated degradation as opposed to internalizing cell surface-expressed proteins, as in the case 
of tetherin antagonism [56, 57]. 
1.3 The HIV Negative factor (Nef) contribution to pathogenesis 
HIV-1 Nef is a multifunctional accessory protein of about 27-35kDa that is abundantly 
expressed early in replication [58, 59]. Myristoylated and mainly localized in the perinuclear 
region, HIV-1 Nef lacks enzymatic activity of its own, but despite this, large deletions in nef 
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have been implicated in the lack of progression to AIDS following eight accidental exposures by 
blood transfusions from a single donor [60-62]. After 17 years, of the nine individuals exposed, 
three infections led to a sufficient drop of CD4+ T cells, classifying these individuals as slow 
progressors. Of the remaining six, three died from causes unrelated to HIV before their 
progression status could be determined. The remaining three have been defined as elite 
controllers [60]. In addition to this clinical observation, experiments in the rhesus macaque SIV-
infection model have demonstrated the importance of the nef gene for SIV-induced pathogenesis 
and robust virus replication in vivo [63]. Transgenic mouse models have also been used to assess 
the role Nef plays in the pathogenesis of HIV-1 in vivo [64-66].  Humanized mice have 
demonstrated that Nef is necessary for robust viral replication and depletion of CD4+ T cells 
[60].  
Bone marrow, liver, and thymus (BLT) humanized mice were used to investigate the role 
of Nef in viral replication and systemic CD4+ T cell loss.  BLT humanized mice infected with an 
HIV-1 defective for nef displayed reduced virus replication and CD4+ T cell cytotoxicity [60]. 
This experiment demonstrates that Nef is critical for virus replication and CD4+ T cell 
cytotoxicity [35, 58, 67].  
However, it will be of great interest to determine which of Nef’s functions are directly 
involved in virus replication and CD4+ T cell cytotoxicity. Although numerous functions have 
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been ascribed to Nef, four in vitro functions have been extensively documented [68-74]: 1)  
downregulatation of cell surface expression of major histocompatibility complex class 1, 2) 
enhanced virion infectivity, 3) activation of p21 protein-activated kinase, and 4) downregulation 
of  surface expression of CD4 in infected cells [58].            
1.3.1 Major Histocombatibility Complex type 1 (MHC1) down regulation by Nef 
MHC1 molecules are found on nearly every nucleated cell and function to display 
peptides generated from within the cells to cytotoxic T cells lymphocytes (CTL) [75, 76]. 
Presentation of foreign peptides by MHC1 generally leads to their destruction by CTLs [77, 78].  
Foreign peptide presentation by MHC1 is specifically designed to eliminate infected cells before 
virus spreads [79, 80]. The process of spreading from infected to uninfected cells is essential to 
the survival of HIV-1; thus, inhibiting foreign peptide presentation by MHC1 is critical. HIV-1 
Nef antagonizes MHC1; understanding the mechanism of this particular Nef activity is still 
ongoing. Nef interacts with the cytoplasmic tail of MHC1 to recruit AP-1 to the cytoplasmic tail 
of MHC-1 and redirects it to the Trans Golgi network on its way to lysosomes where it is 
degraded [81-83]. It has also been proposed that MHC-1 is endocytosed by Nef in an adaptor 
protein 1 (AP-1), phosphofurin acidic cluster sorting protein-1 (PACS-1), and clathrin-dependent 
fashion [84, 85].        
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The downmodulation of MHC1 by Nef has been shown to be important for HIV-1 
replication [86].  Nef-mediated downmodulation of MHC1 is important for the rapid decline of 
CD4+ T cells during HIV-1 infection; however, Nef-induced downregulation of MHC1 does not 
block the development of a dramatic CTL response, which is responsible for the sharp reduction 
in viral load following the acute phase of HIV-1 infection [6].  It has also been shown that HIV-1 
develops escape mutations over the course of the infection [87].  However, Nefs from viremic 
long-term non-progressors were shown to be fully capable of MHC1 downmodulation [88]. 
Two largely incompatible models have been generated that differ as to whether or not 
Nef accelerates MHC1 endocytosis from the cell surface or diverts MHC1 from its normal transit 
to the cell surface directly to the lysosomes for degredation.  In the first model, it was proposed 
that a Nef-induced signal to ARF6 initiated endocytosis from the cell membrane [84].  Initially, 
Nef is directed to the TGN by PACS-1 to be primed by a tyrosine kinase in order to then activate 
PI3K to activate ARNO and subsequently activate ARF6.  By an unknown mechanism ARF6 
triggers endocytosis of MHC1.  Independently, Nef also acts to prevent recycling of internalized 
MHC1 back to the cell surface but no mechanisms have been forthcoming for this process.  In 
recent years, further elaborations have been made to the model with involvement of PACS-2 and 
ZAP70/Syk added [85].  
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Several critical interactions sites on Nef are known to be necessary for the MHC1 
downregulation activity.  In the above model, it is proposed that four glutamate residues (the 
acidic cluster (AC) in Nef (62EEEE65) engage the furin binding region (fbr) of PACS-1.  PACS-2 
may bind to other sorting molecules to target Nef to the trans-Golgi network (TGN).  The 
mutation of the AC in Nef to four alanines abrogates the MHC-1 downregulationfunction.  At the 
TGN a second structural motif of Nef, which is proposed to be an SH3 binding domain 
(72PXXP75), engages an unidentified src family kinase (SFK) that displaces PACS-2 [84].  
SFK/Nef complex would then bind and phosphorylate ZAP70/Syk on tyrosine, enabling 
ZAP70/Syk to bind the SH2 domain of phosphatidylinositol 3-kinase (PI3K) [84].  The resulting 
activation of PI3K would lead to elevated levels of phosphatidylinositol (3,4,5)-triphosphate, the 
stimulation of the guanine nucleotide exchange factor ARNO, and the GTP loading of ARF6 
[84].  This completes the series of events initiated by Nef/PACS-2 binding.  To achieve MHC1 
downregulation, the model continues with activated ARF6 inducing the rapid internalization of 
MHC1 [84].  For the increased rate of MHC1 internalization to be effective in reducing MHC1 
cell surface levels, Nef also blocks the recycling of MHC1 back to the plasma membrane by an 
unknown mechanism.  This last Nef activity is specifically disabled by the M20A mutation.  In 
summary, the steps leading to the ultimate sequestration of MHC1 to the TGN are defined by 
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three mutant Nefs, (62AAAA65, 72AXXA75, and M20A), all of which result in the crippling of 
MHC1 downregulation.   
An alternate model proposes a ternary complex between Nef, adaptor protein 1 (AP-1) 
and the cytoplasmic tail of MHC1.  This complex is responsible for the misdirection of MHC1 
away from the cell surface [89-91].  The roles for 62EEEE65 and 72PXXP75 are radically different 
in this model.  The tetraglutamate is not viewed as an acidic cluster and 72PXXP75 is not an SH3 
domain-binding site.  These interpretations were confirmed by fine structure-function mapping 
[92, 93].  Specifically only two of four glutamates were sufficient for full function.  Also, 
mutation of the 72PXXP75 putative SH3 domain binding failed to conform to the canonical 
expectation that activity would be completely lost by single mutations AXXP or PXXA [94-97].  
Critically, mutation to alanine of a highly conserved proline at positions 78 (and hence outside of 
the proposed SH3 domain binding site) did eliminate MHC1 downregulation activity [93, 98, 
99].  The validity of the second model was confirmed by X-ray crystal analysis of the Nef, 
MHC1 cytoplasmic tail and AP-1 complex.  The glutamates interacted with a basic patch on AP-
1 to stabilize the ternary complex, and the three prolines (72,75, and 78) were strung out in a 
unique confirmation unlike Sh3 binding domains.  A critical interaction was observed between 
P78 of Nef and a pocket formed by the cytoplasmic tail of MHC1 in association with the 
YXXΦ site of AP-1 [82]. 
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The role of M20 remains obscure though a computer model predicts binding of a region 
of Nef around M20 to the YXXΦ site of AP-1 [100].  The above-mentioned X-ray crystal 
structure and the computer model have not been reconciled.  
Finally, the mutation of the highly conserved, multifunctional residue aspartate-123 
eliminated MHC1 downreulation activity [101, 102].  Until the roles of M20 and D123 are 
resolved the full mechanism of Nef’s downregulation of MHC1 will remain unknown.  However, 
much has been learned about the mechanism of Nef’s MHC1 downreulation activity that should 
provide a basis for developing small molecule inhibitors [103].  What remains to be determined 
is the importance of this activity for the development of AIDS.  
1.3.2 Downregulation of cell surface expression of CD4 by Nef 
 The downregulation of CD4 from the cell surface by Nef was the first and is the most 
extensively characterized function of the Nef protein [26, 104]. This particular function of Nef is 
highly conserved with Nefs from HIV-1 groups M, N, and O as well as Nefs from SIVcpz, all of 
which are capable of downregulating surface expression of CD4 [105]. Differences between 
group M subtypes have been reported in Nef’s ability to downmodulate CD4 [106].  
Downmodulation of CD4 by Nef involves internalizing surface CD4 [107], which requires the 
clathrin-associated adaptor protein 2 (AP-2) [108]. In addition, the internalization of surface CD4 
is independent of the phosphorylation of serine residues in the CD4 cytoplasmic tail [26].  
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As mentioned, Nef has no enzymatic activity of its own and the internalization of CD4 
requires cellular components.  X-ray crystallography and nuclear magnetic resonance studies 
have demonstrated that Nef has flexible N-terminal (amino acids 1-68), a central structured core 
(amino acids 69-197) and a short C-terminal segment (amino acids 198-206).  Within the 
structured core is a flexible loop (amino acids 146-179) [109-111].  Within this loop are two 
motifs critical for CD4 downregulation – a canonical dileucine trafficking motif (Leu164 and 
Leu165) and diacidic motif (aspartate or glutamate at 174 and aspartate at 175) that is specific to 
Nef [108, 112, 113].  The dileucine sequence in SF2 Nef is 160ENNSLL165.  The glutamate and 
two leucines are highly conserved but the internal residues are not [114].  Position 174 of the 
acidic motif is highly conserved as an acidic residue and position 175 is strictly conserved as 
aspartate.  Yeast-3-hybrid assays have shown that the two motifs are both involved in the binding 
of Nef to AP-2 with the formation of a ternary complex with the cytoplasmic tail of CD4 [108, 
113].  The Nef-directed binding of CD4 to AP-2 has been proposed as the mechanism for 
enhanced endocytosis of CD4.   
The dileucine motif in Nef has been investigated by mutational analysis.  Mutation of 
E160, N161, N162, or S163 to glycine has little effect on the capacity of Nef to downregulate 
CD4 [115].  However, the charge reversing mutation of E160 to lysine reduces activity by 50%.  
A possible role for the three internal residues (N161, N162, or S163) has been tested by 
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replacing them with RQP, which is found in the dileucine motif of tyrosinase [108].  The mutant 
Nef was fully active for CD4 downregulation and this activity was only marginally dependent on 
the diacidic motif.  Hence, the Nef dileucine motif (ENNSLL) is suboptimal relative to the 
tyrpsinase motif (ERQPLL) and it is compensated for by the contribution of the diacidic motif to 
binding.  The diacidic residues have been proposed to stabilize the ternary complex by 
interacting with two basic residues present in AP-2, lysine-297 and arginine-340, on the alpha-
adaptin trunk domain [113].  The mutation of these residues specifically inhibits the ability of 
Nef to bind AP-2 and downregulate CD4. 
A possible explanation for this complex situation instead of a direct canonical interaction 
between the Nef dileucine motif and AP-2 is that the Nef dileucine motif is multifunctional and 
interacts with not only AP-2 but also AP-1.  The diacidic motif allows the dileucine motif that is 
otherwise optimized for AP-1 binding to also function for AP-2 binding.  The direct dileucine-
dependent binding of Nef to AP-1 has been demonstrated by in vitro pull down assays [89, 91, 
115].  This Nef interaction with AP-1 is distinct from the MHC1 cytoplasmic tail, Nef and AP-1 
non-canonical interaction described above.  A functional role for a direct Nef/AP-1 binding has 
not yet been discovered.   
In addition to the diacidic and dileucine motifs, the internalization of CD4 from the cell 
surface requires Nef to be myristoylated, which allows Nef to be relocated from the cytosol to 
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cellular membranes [116].  It is at the plasma membrane that the Nef flexible loop (amino acid 
146-179) engages AP-2, which allows binding to the cytoplasmic tail of CD4 and results in the 
internationalization of CD4 followed by trafficking to the lysosomes [107, 112, 113, 116-123].   
Additional Nef residues are necessary for the CD4 internalization.  Mutation of 
tryptophan 57 and leucine 58 to alaninie on the N-terminal flexible arm also renders Nef inactive 
for CD4 downregulation as does the mutation of aspartate 123 in the structured core [101, 124].  
In the results section, we discovered a new pair of residues that are required for CD4 
downregulation -aspartate 36 and leucine 37.  As was the case for MHC1 downregulation much 
remains to be resolved before understanding of CD4 downregulation by Nef is complete.        
1.3.3 Enhancement of virion infectivity 
In vitro single-round infectivity assays have demonstrated that, in the absence of Nef, 
HIV-1 infectivity is decreased [125, 126]. However, full infectivity can be rescued in assays in 
which a nef-defective virus is complemented by exogenous expression of Nef in the producer 
cell [126, 127].  This effect does not involve the downregulation of CD4 as production of virus 
in cells, like 293T, that does not express CD4 yields defective virus without Nef. The precise 
mechanism behind this effect is poorly understood; however, investigations have shown that 
Nef-mediated enhancement of infectivity occurs early in infection [128, 129]. Two investigations 
have supported this claim but propose different mechanisms: 1) Nef may increase viral DNA 
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synthesis and 2) Nef affects viral entry [129-132]. Early reports demonstrated that Nef has no 
impact on viral entry, but does impact viral replication [126, 131, 133]. 
An important study of the mechanism of enhancement of HIV-1 infectivity by Nef has 
uncovered a role of dynamin 2.  Co-immunoprecipitation assays following expression of HA-
tagged Nef in 293T cells revealed a prominent protein band of 100kD that was absent from 
control precipitation [134].  This protein was shown by liquid chromatography-coupled tandem 
mass spectrometry to be dynamin-2.  The specificity of the Nef-dynamin-2 interaction was 
shown by the fact that dynamin-1 and dynamin-3 do not bind Nef [134].  A mutational analysis 
of Nef was performed and it was determined that three surface-exposed domain residues, leucine 
112, phenylalanine 121 and aspartae 123 were critical for dynamin-2 binding.  Mutation of each 
of there residues to alanine blocked the capacity of Nef to enhance viral infectivity.  The SH3 
binding domain (PXXP) and dileucine motif (EXXXLL) of Nef were not important for dynamin-
2 binding but did inhibit enhancement of viral infectivity by 50 and >90 percent respectively 
when mutated to alanine.  The dramatic dependence of viral infectivity on the dileucine motif 
suggests that Nef bound to dynamin-2 also interacts with an adaptor protein.   
Pizzato reported that the unusual murine leukemia virus protein, glycosylated Gag can 
replace Nef the enhancement of virion infectivity [135].   This MLV protein is produced from a 
CUG initiation codon upstream of the Gag AUG codon.  GlycoGag contains a membrane 
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spanning domain and inserts into the ER membrane with the N-terminus in the cytoplasm and 
the usual Gag sequence in the lumen of the ER where it becomes glycosylated.  There are about 
60 amino acids in the cytoplasm derived from the upstream coding sequence before the standard 
gag AUG.  This suggests that glycosylated Gag functions at the inner surface of the cell 
membrane which is the site of virion budding.  In the case of Nef-induced enhancement of viral 
infectivity the site of virion budding at the inner surface of the cell membrane could also be the 
site where Nef acts since this activity requires myristylation of the N-terminus [134].     
1.3.4 Activation of p21 activated protein kinase 2 (Pak2) by Nef  
Immune activation is associated with increased viral loads and disease progression [136].  
Fackler and colleagues postulated that Nef can regulate activation of the infected cell through 
interactions with Pak2. Investigations have also demonstrated that Nef forms a complex with 
Pak2 and induces its autophosphorylation and activation [93].  Pak2 is a member of a family of 
proteins whose common functions include modulating the signaling cascades that lead to 
cytoskeletal remodeling, regulating apoptosis, and regulating transcription [137]. The biological 
importance of the Nef-Pak2 interaction is poorly understood and not all Nefs activate Pak2 
equally [138-140].  However, it has been determined that a cellular SH3 domain protein is 
involved.  By precise mutational analysis it can be determined if the protein is interacting with an 
unknown SH3 domain protein by the unique characteristics of proline rich SH3 domain binding 
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site interaction with SH3 domain proteins [94, 96, 97].  The full type II SH3 domain binding 
motif is PXXPXR which corresponds to the Nef sequence – 72PQVPLR77.  Mutations of either of 
the prolines or the arginine should massively reduce the ability of the motif to bind to its SH3 
domain partner.  The identities of the “X” residues vary and provide specificity for the binding, 
which is critical as the human genome contains 300 SH3 domain proteins [141].  As noted 
above, the single mutation of the prolines of the Nef SH3 binding domain does not fully block 
the MHC1 downregulation activity, nor was the mutation of arginine 77 effective in preventing 
Nef from downregulating MHC1 [93].  In contrast each of these mutations prevented Nef from 
activating Pak2 [93].  This was also the case for the binding of Nef to the SH3 domain of the 
tyrosine kinase, Hck [93, 142-144].  Consistent with the SH3 domain binding motif model the 
effect of mutating internal residues (“X”) varied between Pak2 activation and Hck binding [93].  
Therefore the Nef SH3 binding site is capable of binding to different SH3 domain proteins and 
exhibits a similar flexibility to the dileucine motif to be involved with different host proteins to 
bring about different functions.           
Pak2 activation, enhancement of virion infectivity, and MHC1 downmodulation by Nef, 
all rely on the presence of the polyproline segment P69VRPQVPLRP78 [93]. However, the 
PXXPXR motif is dispensable for pathogenesis. Rhesus macaques infected with a virus with a 
mutated PXXPXR motif had high viral loads and developed AIDS-like symptoms [145, 146]. 
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These results indicate that MHC1 downmodulation, Pak2 activation, and enhanced virion 
infectivity are all functions of Nef that are dispensable for robust viral replication and CD4+ T 
cell depletion.          
1.4 CD4 as an innate restriction factor of HIV-1 
Two genes, namely nef and vpu, are not found in lentiviruses that infect horses, cows, 
goats, sheep, or cats [8, 17].  While both Nef and Vpu are multifunctional, which functions of 
these two proteins have a major impact on the ability of HIV-1 to actively replicate and induce 
pathogenesis remains unclear [43]. Of particular interest is the genes’ role in adapting primate 
viruses to infect CD4+ T cells [147]. Using CD4 as the primary viral receptor is difficult because 
there are 100,000 molecules of CD4 on the surface of CD4+ T cells [148]. Presumably this is not 
a problem for viral entry but it is very likely that CD4 within the infected cell can block the 
production of infectious virions by binding of CD4 to Env in the ER [149].  
In human lymphoid tissue, Nef-mediated downmodulation of CD4 has been shown to 
correlate with both viral replication and CD4+ T cell depletion [150].  Nefs from an AIDS patient 
have enhanced CD4 downmodulation when compared to Nefs from an asymptomatic patient 
[146, 150, 151].  Of interest is that the infectivity of virus from AIDS patients is also higher than 
infectivity of viruses from asymptomatic patients [146]. Taken together, these two observations, 
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an ex vivo and an in vitro investigation, suggest that CD4 downmodulation is important for both 
CD4+ T cell depletion and robust viral replication [146, 150].           
Using the BLT humanized mouse I have determined that HIV-1 LAI containing a Nef 
mutated to be specifically defective for CD4 downregulation is attenuated in replication and 
pathogenesis [152]. The CD4+ T cell cytotoxic phenotype represents approximately 50% of the 
overall defective phenotype of virus devoid of Nef expression [60]. The highly significant 
impairment of HIV-1 fitness that results from specifically mutating nef to be defective for CD4 
downregulation demonstrates the importance of this function for the simian/human lentiviruses, 
which appears concomitant with the expansion of viral tropism to include CD4-expressing T 
cells.  Remarkably, we have also found that the complete inactivation of vpu gives a phenotype 
similar to that observed for nef specifically mutated to lack CD4 downregulation [153].  Vpu, 
like Nef, acts to reduce the cellular content of CD4 [154]. The similarity of the phenotypes 
suggests a common mechanism of incomplete blocking of the capacity of intracellular CD4 to 
interfere with HIV-1 replication. 
1.5 Other Nef activities that may be important for HIV-1 replication and pathogenesis. 
 There are Nef activities in addition to Pak2 and Hck activation that are dependent on an 
intact SH3 binding site, including upregulation of FasL and PD-1 and Lck-dependent activation 
Ras-Erk signaling to promote the production of the T lymphocyte survival factor IL-2 [155-158].  
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To address the possibility that these activities may significantly impact HIV-1 replication and 
pathogenesis in BLT humanized mice I mutated prolines 72 and 75 to alanine to prevent 
interactions between Nef and host cell SH3 domain proteins [152].  This mutation did not exhibit 
a negative effect on Nef function in BLT humanized mice.  One explanation for this counter 
intuitive observation is that high levels of replication and rapid reduction in CD4+ T cell and 
CD4+ CD8+ thymocytes depends on only a few Nef activities.   
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CHAPTER 2: IN VIVO ANALYSIS OF HIGHLY CONSERVED NEF ACTIVITIES IN HIV-1 
REPLICATION AND PATHOGENESIS1 
2.1 Summary 
Background: The HIV-1 accessory protein, Nef, is decisive for progression to AIDS. In vitro 
characterization of the protein has described many Nef activities of unknown in vivo significance 
including CD4 downregulation and a number of activities that depend on Nef interacting with 
host SH3 domain proteins.  Here, we use the BLT humanized mouse model of HIV-1 infection to 
assess their impact on viral replication and pathogenesis and the selection pressure to restore 
these activities using enforced in vivo evolution. 
Results: We followed the evolution of HIV-1LAI (LAI) with a frame-shifted nef (LAINeffs) 
during infection of BLT mice.  LAINeffs was rapidly replaced in blood by virus with short 
deletions in nef that restored the open reading frame (LAINeffsΔ-1 and LAINeffsΔ-13). These in 
vivo generated mutations were incorporated into Nef expression vectors for in vitro analysis.  
 
1 This chapter appeared as an article in the journal Retrovirology.  The original citation is as 
follows: Richard L Watkins, Wei Zou, Paul W Denton, John F Krisko, John L Foster and J 
Victor Garcia. In vivo analysis of highly conserved Nef activities in HIV-1 replication and 
pathogenesis. Retrovirology 2013, 10:125. RW, WZ, PD, JK, and JF performed experiments 
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The LAINeffsΔ-1 and LAINeffsΔ-13 were stably expressed and specifically defective for CD4 
downregulation.  Subsequently, LAINeffsΔ-1 was often replaced by wild type LAI. 
Unexpectedly, LAINeffsΔ-1 three-fold reduced viral replication (compared to LAI) and a 50% 
reduction of systemic CD4+ T cells (>90% for LAI) demonstrating the importance of CD4 
downregulation. These results also demonstrate that functions other than CD4 downregulation 
enhanced viral replication and pathogenesis of LAINeffsΔ-1 and LAINeffsΔ-13 compared to 
Nef-defective LAI. To gain insight into the nature of these unknown activities, we constructed 
the double mutant P72A/P75A. Multiple Nef activities can be negated by mutating the SH3 
domain-binding site (P72Q73V74P75L76R77) to P72A/P75A and this mutation does not affect 
CD4 downregulation.  Virus with nef mutated to P72A/P75A closely resembled the wild-type 
virus in vivo as viral replication and pathogenesis was not significantly altered. Unlike LAINeffs 
described above, the P72A/P75A mutation had a very weak tendency to revert to wild type 
sequence.   
Conclusions: The in vivo phenotype of Nef is significantly dependent on CD4 downregulation 
but minimally on the numerous Nef activities that require an intact SH3 domain binding motif.   
These results suggest that CD4 downregulation plus one or more unknown Nef activities 
contribute to enhanced viral replication and pathogenesis and are suitable targets for anti-HIV 
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therapy.  Enforced evolution studies in BLT mice will greatly facilitate identification of these 
critical activities. 
2.2 Introduction 
 Patients infected with nef-defective HIV-1, have strongly attenuated viral replication and 
pathogenesis [62, 159-161]. In vitro studies have defined numerous Nef activities but how this 
206 amino acid protein has such a major effect on the outcome of HIV-1 infection in patients is 
unknown [8, 124, 162-164]. One view of Nef’s overall impact on HIV-1 infection is that there is 
a cumulative effect of multiple activities to achieve high viral loads resulting in the development 
of AIDS [35, 165].  In support of this view, a number of Nef activities have been found to be 
conserved in monkey, ape and human immunodeficiency viruses [105, 166-170].  A difficulty 
with this interpretation is that there are so many Nef activities that the effect of any given activity 
on replication and pathogenesis would be small.  Alternatively, one or a few Nef functionalities 
may be the major contributors to viral replication and pathogenesis. In this regard CD4 
downregulation, a highly conserved Nef function, is of particular interest. Ex vivo studies with 
activated peripheral blood T cells and cultures of tonsil tissue support a dominant role for CD4 
downregulation in establishing high rates of viral replication [150, 171, 172].  Another factor that 
may be critical is the Src homology region 3 (SH3) domain-binding site in Nef’s polyproline 
helix [93, 173, 174].  This ten amino acid segment (PVRPQVPLRP) is the most highly 
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conserved stretch of amino acids in the protein [175].  Evidence exists for SH3 domain binding 
site involvement with enhanced viral replication [93, 134, 174], cytotoxic effects [155, 156, 176-
178], activation of Hck [144] and antagonism of host immune responses [84, 179-182]. Nef 
structure/function studies have documented that the CD4 downregulation activity and the SH3 
domain protein dependent activities are genetically distinct [93, 127, 183]. 
 To gain greater understanding of the roles of Nef’s diverse activities during HIV-1 
replication we have employed the BLT humanized mouse model.  This model has stable 
reconstitution of a full spectrum of human immune cells and has been used to investigate a 
number of different aspects of HIV-1 infection [60, 87, 184-187]. With regard to Nef, we have 
previously compared the replicative properties of HIV-1LAI (LAI) and LAI with two large 
deletions in nef coding sequence (LAINefdd) in BLT mice [60]. LAI exhibited high levels of 
viral replication and near total depletion of CD4+ T cells in blood and tissues, as well as, 
depletion of CD4+ CD8+ thymocytes from the human thymic organoid. LAINefdd had 
significantly reduced viral replication and dramatically reduced capacity for inducing CD4+ T 
cell and CD4+ CD8+ thymocyte loss [60].  However, one important aspect of HIV-1 infection of 
BLT humanized mice that has not yet been investigated is the ability of nef to evolve during 
HIV-1 infection. In patients, HIV-1 nef extensively mutates resulting in tremendous sequence 
diversity but it has not been possible to clearly relate these changes to Nef activities or the 
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pathogenic potential of the virus [146, 151, 175, 188-190]. Here, we investigate three critical 
features of Nef’s role during HIV-1 infection: 1) the ability of the virus to mutate nef sequences 
to gain enhanced replicative fitness, 2) the role of CD4 downregulation in viral replication and 
pathogenesis and 3) the importance of Nef’s interactions with host SH3 domain proteins in 
replication and pathogenesis.  We find that Nef induced CD4 downregulation is highly 
significant for active viral replication and pathogenesis.  In addition, there are unidentified 
function(s) that contribute to viral replication and/or CD4+ T cell depletion and are necessary for 
Nef’s full pathogenic potential.  Importantly, this latter function or functions does not depend on 
interactions with host cell SH3 domain proteins. 
2.3 Experimental Procedure 
2.3.1 Preparation of BLT humanized mice  
 BLT humanized mice were prepared as previously described [60, 87, 185, 186, 191-198]. 
Briefly, thymus/liver implanted or NOD/SCID IL-2γ-/- mice (The Jackson Laboratories, Bar 
Harbor, ME) were transplanted with autologous human CD34+ cells isolated from fetal liver 
(Advanced Bioscience Resources, Alameda, CA). Human reconstitution in the peripheral blood 
of these mice was monitored periodically by flow cytometry (FACSCanto; BD Biosciences). 
Mice were maintained either at the Animal Resources Center, UT Southwestern Medical Center 
at Dallas (UTSWMC) or at the Division of Laboratory Animal Medicine, University of North 
 28 
Carolina at Chapel Hill (UNC-CH) in accordance with protocols approved by the UTSWMC or 
UNC-CH Institutional Animal Care and Use Committees.  
 To ensure genetic diversity, fifteen different tissue donors were used to generate five 
groups of mice used for the experiments presented in this manuscript. The overall level of 
engraftment for all the mice used for these experiments was 60.9% + 3.2% (n = 27).  None of the 
groups (Naïve, LAI, LAINeffsΔ-1, LAINeffsΔ-13 and LAINefP72A/P75A) had significantly 
different engraftment levels compared to any of the other groups (p> 0.1535). All groups had at 
least two different human genetic backgrounds included in the evaluation of infection. 
LAINeffsΔ-1, LAINeffsΔ-13 and LAINefP72A/P75A infected groups each shared a common 
donor with the LAI infected group. 
2.3.2 Cell lines and culture conditions  
 HeLa Magi and TZM-bl cells were maintained in Dulbecco's modified Eagle's medium 
(DMEM; Cellgro, Herndon, VA) supplemented with 10% fetal bovine serum (FBS; Cellgro), 
100 IU/ml of penicillin, 100 µg/ml streptomycin, and 2 mM glutamine (Cellgro) in 10% CO2 at 
37°C.  Similarly, 293T cells were cultured under the same conditions as TZM-bl and HeLa Magi 
cells but in 5% CO2. The human CEM T cell line was cultured in RPMI 1640 medium 
supplemented with 10% fetal bovine serum (Hyclone), 50 IU of penicillin per ml, 50 µg 
streptomycin per ml, 2 mM L-glutamine and 1 mM sodium pyruvate in 10% CO2 at 37°C. 
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2.3.3 Proviral clones  
 The proviral clone, pLAI (accession # K02013), was described by Peden et al [199]. 
pLAINeffs was constructed to be defective for nef by cutting with XhoI, filling in with Klenow 
and re-ligating. This leaves nef sequence intact but introduces a four-base frame-shift after nef 
codon 35. The one base deletion (8501) and thirteen base deletion (8511-8523) found in nef 
sequences from LAINeffs infected mice were inserted into pLAINeffs by site directed 
mutagenesis to produce pLAINeffsΔ-1 and pLAINeffsΔ-13, respectively.  
2.3.4 Virus production, exposure of BLT mice to HIV-1LAI and HIV-1LAI with mutated nefs, 
tissue harvesting and flow cytometric analyses.  
 Stocks of LAI, LAINeffs, LAINeffsΔ-1, LAINeffsΔ-13 and LAINefP72A/P75A were 
prepared and titered as we previously described [200, 201]. Briefly, proviral clones were 
transfected into 293T cells. Viral supernatant was collected 48 hours after transfection and 
diluted in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum, 100 IU penicillin/ml, 100 ug/ml streptomycin, and 2 mM glutamine. TZM-bl cells were 
infected in 12-well tissue culture plates with 0.4 ml of virus at multiple dilutions in medium for 
two hours. Then, 1.0 ml of supplemented DMEM was added and the plates incubated overnight. 
Virus containing medium was removed the next day, replaced with fresh DMEM plus 10% fetal 
bovine serum and the incubation continued for 24 hours. The cells were fixed and stained with 5-
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bromo-4-chloro-3-indolyl-β-D-galactopyranoside (40 hours after first exposure to virus). 
Individual blue cells were counted directly to determine infectious particles per ml (TCIU). Each 
titer of these viral stocks was performed in triplicate and at least two different titer 
determinations were performed for each virus preparation. 
 Intravenous exposure of BLT mice with infectious virus was conducted via tail vein 
injection with the indicated tissue culture infectious units (TCIU). Viral load in peripheral blood 
of infected mice was monitored longitudinally by quantitative real-time PCR using Taqman 
RNA to-CTTM 1-step kit from Applied Biosystems, USA [192, 193, 202]. The sequences of the 
forward and reverse primers and the Taqman probe for PCR were: 5’-
CATGTTTTCAGCATTATCAGAAGGA-3’, 5’-TGCTTGATGTCCCCCCACT-3’, and 5’-
FAM CCACCCCACAAGATTTAAACACCATGCTAA-Q-3’, respectively.  
 CD4+ and CD8+ T cell levels were monitored by flow cytometric analysis as previously 
described [185, 196, 198]. Immunophenotyping was performed on blood samples collected 
longitudinally and on mononuclear cells isolated from tissues at harvest. Whole peripheral blood 
(PB) from humanized mice was analyzed according to the BD Biosciences Lyse/Wash protocol 
(Cat. No. 349202) as we have previously described [203]. Briefly, following antibody labeling of 
whole blood, red blood cells were lysed. The remaining cells were washed, fixed and the sample 
was analyzed by flow cytometry. Tissue mononuclear cell isolations and immunophenotyping 
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analyses were also performed according to published methods [185, 196, 198]. Flow cytometric 
gating for CD4 and CD8 cell surface expression was performed as follows: (step 1) forward and 
side scatter properties were utilized to set a live cell gate; (step 2) live cells were then analyzed 
for expression of the human pan-leukocyte marker CD45; (step 3) human leukocytes were then 
analyzed for hCD3 and (step 4) these T cells or thymocytes were analyzed for hCD4 and hCD8 
expression.  
 The panel of antibodies for analysis of CD8+ T cells double positive for CD38+ and HLA-
DR+ was CD8 FITC (SK1), HLA-DR, PE (TU36) or IgG2bκ PE, CD4 PerCP (SK3), CD3 PE-
Cy7 (SK7), CD38 APC (HB7) or IgG1κ APC, and CD45 APC-Cy7 (2D1) (all purchased from 
BD Biosciences). Gating was performed as follows: (step 1) forward and side scatter properties 
were utilized to set a live cell gate; (step 2) live cells were then analyzed for expression of the 
human pan-leukocyte marker CD45; (step 3) human leukocytes were then analyzed for CD3; 
(step 4) T cells were analyzed for CD4 and/or CD8 expression; (step 5) activation of human 
CD8+ T cells was analyzed for HLA-DR and CD38 expression [186]. Gates defining HLA-DR 
and CD38 expression were set with isotype-matched flourophore-conjugated antibodies.  
2.3.5 Viral Replication in vitro  
 The human T-cell line A3.01 (NIH AIDS Reagent Program) was used to propagate both 
wild-type and nef-mutant HIV-1LAI.  Cells were infected with virus stocks at a multiplicity of 
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infection (MOI) of 0.05 in complete RPMI (containing 10% fetal bovine serum (Hyclone), 50 IU 
of penicillin per ml, 50 µg streptomycin per ml, 2 mM L-glutamine, and 1 mM sodium pyruvate) 
plus 2 µg/ml polybrene at 37o C, 5% CO2 for 4 hours.  The cells were washed extensively with 
PBS and cultured at 37o C, 5% CO2 in complete RPMI.  Cell cultures were passaged twice 
weekly at which time a sample of the culture supernatant was collected for quantification of viral 
capsid protein by p24gag ELISA (HIV-1 p24 Antigen Capture Assay (Advance Biosciences 
Library, Inc., #5421).  
2.3.6 In vitro analysis of Nef activities  
 The site directed mutations of nef in pLAINeffsΔ-1, pLAINeffsΔ-13 and 
pLAINefP72A/P75A were subcloned into pLXSN, a retroviral vector for transduction of CEM T 
cells and into pcDNA3.1 for transfection into 293T cells [93]. Assays for CD4 downregulation, 
MHCI downregulation, and activation of PAK2 were described previously [93]. Enhancement of 
virion infectivity was determined by single infection assays using HeLa-MAGI indicator cells 
with virus produced from proviral clones transfected into 293T cells [93, 204]. Protein 
expression was determined by Western Blot analysis with sheep anti-Nef antibody or mouse 
monoclonal anti-Nef [93, 205]. 
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2.3.7 Sequence analysis of plasma virion RNA  
 Viral RNA was extracted from 20 µl of plasma from infected mice using the QIAamp 
Viral RNA Mini kit (Qiagen Sciences, USA). RNA was then reverse transcribed into cDNA, 
which was then subjected to nested PCR. The outer primers for nef amplification are 5’-
AGCTTGCTCAATGCCACAGCC-3’ and 5’-GCTGCATATAAGCAGCTGCTTTTTG-3’. The 
inner primers are 5’-TAGAGCTATTCGCCACATACC-3’ and 5’-
GCTTGCTACAAGGGACTTTCCGC-3’. Gel purified PCR products were sequenced and the 
sequences were aligned to HIVLAI sequences to determine if nucleotide changes had occurred. 
2.3.8 Statistics  
 Mann-Whitney tests were performed in Prism version 5 (Graph Pad). All data plotted as 
mean + S.E.M. 
2.4 Results 
 With the exceptions of vif and pol, the ability of HIV-1 to correct defective genes in vivo 
and regain function has not been investigated [206, 207]. Determining the selection pressure for 
Nef functions is a key component for characterizing the overall importance of Nef and the 
phenotypic contribution of its individual activities.  In addition, it provides an opportunity to use 
enforced selection to discern what structural/functional motifs of Nef are important in vivo. To 
address the mutational response of the virus to a defective nef, we generated an inactivating 
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mutation by filling in the 5’ four-base overhang generated by the XhoI restriction endonuclease 
at codon 35 with Klenow (Figure 2.1 A). This insertion resides 5’ of the polypurine tract and 
does not alter the synthesis of gag-encoded proteins (Figure 2.1 B) or alter the in vitro replication 
properties of the virus (Figure 2.1 C).  
 LAI and the nef frame-shifted LAI (LAINeffs) were injected intravenously (iv, 360,000 
TCIU) into BLT mice. Three LAI infected mice were monitored over eight weeks for virus in the 
blood.  These mice had peak viral loads of 12.2 + 4.7 x 106 copies of viral RNA.  No changes 
were observed in nef sequence after eight weeks of the infection (Figure 2.2 A).  The LAINeffs 
inoculated mice were also monitored longitudinally for the presence of virus in plasma.  
LAINeffs infected mice exhibited active viral replication with peak viral loads of 2.26 + 0.72 x 
106 copies of viral RNA per ml of blood  (n = 7). We sequenced nef from viral RNA in blood 
from two to eight weeks post-infection and found that the frame-shifted LAINeffs (designated 
“+4”) was initially replaced by one of two nef sequences with restored open reading frames 
(Figure 2.2 A).  One mouse (LAINeffs 1) had a thirteen base deletion downstream of the original 
four base insertion (Δ-13). In the other six cases (LAINeffs 2-7), the nef coding sequence also 
retained the four base insertion but lost one base in a run of five adenines just downstream of the 
original insertion site (Δ-1).  The original LAINeffs (+4) was not detectable in blood by five 
weeks post infection in any of the seven mice. In two mice, and by a slower process, wild type 
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nef appeared by 4-7 weeks (LAINeffs 4, 5).  After eight weeks, four mice (LAINeffs 3, 4, 5 and 
6) were predominantly infected with a virus containing wild type nef (not shown). In summary, 
in the blood of all of the mice inoculated with LAINeffs the original defective nef was replaced 
by a nef mutant that restored the open reading frame. Sequences determined at eight weeks 
yielded four mice with exact removal of the four base insertion (WT), two mice with Δ-1 and 
one mouse with Δ-13. These results support the conclusion that a strong positive selection exists 
for a functioning nef.  
 The amino acid sequences of the restored nefs are reported in Figure 2.2 B. The changes 
in Nef sequence resulting from the one base deletion (LAINeffsΔ-1) and the thirteen base 
deletion (LAINeffsΔ-13) were the replacement of three amino acids (DLE, 36-38) in wild type 
LAINef with four missense amino acids (SRPG) and the replacement of ten wild type amino 
acids (DLEKHGAITS, 36-45) with seven missense amino acids (SRPGKTC), respectively 
(Figure 2.2 B). The sequencing data suggested that virus with fsΔ-1 and fsΔ-13 nefs had a strong 
replicative advantage over the nef-defective virus. However, the replacement of LAINeffsΔ-1 
with wild type (WT) virus in four mice further suggests a replicative advantage for wild type nef 
over revertant nefs. Based on these in vivo findings, we were interested in characterizing the in 
vitro activities of the Δ-1 and Δ-13 mutant Nefs.  
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2.4.1 In vitro functional analysis of nef mutants that evolved in vivo  
 To assess in vitro phenotypes of the Nefs expressed by LAINeffsΔ-1 and LAINeffsΔ-13, 
we transferred the coding sequences into the retroviral expression plasmid, pLXSN, and 
produced retroviral vectors [26]. CEM T cells expressing wild type and mutant Nefs were 
assayed for level of expression, CD4 downregulation and MHC Class I (MHCI) downregulation 
activities (Figure 2.3 A). The mutant forms of Nef were expressed at the same level as wild type 
Nef (Figure 3A, Upper Panel, α-Nef). Flow cytometric analysis of cell surface CD4 and MHCI 
expression of CEM T cells that were transduced to express LAI Nef yielded the well-known 
patterns for the downregulation of these proteins (Figure 2.3 A, Lower Panel, [26, 93, 208]). 
Both LAI NeffsΔ-1 and LAI NeffsΔ-13 proteins were fully active for MHCI downregulation but 
devoid of CD4 downregulation activity. To assess the effect of the two mutations on Nef’s 
interaction with p21 activated protein kinase (PAK2), we expressed the NeffsΔ-1 and NeffsΔ-13 
proteins from pcDNA3.1 in transfected 293T cells.  We determined the capacity of these Nefs to 
activate PAK2 using an in vitro kinase assay (IVKA, [93, 200, 209]). Again, both mutant 
proteins were expressed at the same level as wild type LAI Nef (Figure 2.3 B, α-Nef) and both 
proteins activated PAK2 although at a reduced level for LAI NeffsΔ-13 (Figure 2.3 B, α-PAK2 
IVKA). We also generated the proviral clones, pLAINeffsΔ-1 and pLAINeffsΔ-13, to 
characterize the enhancement of infectivity function of these Nefs. Virus was produced from 
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transfected 293T cells and assayed with HeLa MAGI indicator cells. In this single infection 
assay, a reduction in the number of infected cells per ng of virion p24gag is observed for 
LAINeffs relative to LAI (Figure 2.3 C). LAINeffsΔ-1 and LAINeffsΔ-13 both exhibited higher 
infectivities than LAINeffs in this assay but were not significantly different from LAI (Figure 2.3 
C). Finally, in Figure 3D, the capacities of LAINeffsΔ-1 and LAINeffsΔ-13 to replicate in A3.01 
cells were observed to be the same as LAI (Figure 2.3 D).   On the basis of this data, we 
concluded that LAINeffsΔ-1 and LAINeffsΔ-13 exhibited a specific loss of the CD4 
downregulation activity and were potentially useful to investigate the impact of CD4 
downregulation by Nef on HIV-1 infection in BLT mice. However, the question remained 
whether these nefs could revert to wild type sequence in vivo as four of seven mice infected with 
LAINeffs had predominantly the wild type nef sequence in blood after eight weeks (Figure 2.2 
A).  It should be noted that reversion of the Δ-1 mutation to wild type would require two steps, a 
four-base deletion and a one base insertion of adenosine. We judged this two-step process to be 
unlikely to occur within the time frame of the experiments. Accordingly, the wild type nefs 
found in four of the seven mice by week eight may have been directly generated from the frame-
shifted nef in LAINeffs by the exact removal of the four-base insertion.   
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2.4.2 Infection of BLT humanized mice with in vivo generated nef mutations  
 LAI, LAINeffsΔ-1 and LAINeffsΔ-13 were intravenously injected (90,000 TCIU) into 
BLT mice.  In Figure 2.4, the positive control, wild type LAI, and the negative control, 
uninfected mice (Naïve), are compared to LAINeffsΔ-1 and LAINeffsΔ-13 infected mice. In 
Figures 2.4 A and C, LAI inoculation was followed with rapid appearance of viral RNA in blood 
and replication to high levels (peak viral loads, 3.03 + 0.54 x 106 copies viral RNA per ml of 
plasma, n = 7). The time course for the infections with LAINeffsΔ-1 and LAINeffsΔ-13 revealed 
a reduction in viral replication compared to LAI (Figure 2.4 A and C). The average peak viral 
load (in millions of RNA copies per ml of plasma) for LAINeffsΔ-1 was 1.19 + 0.26 (n = 4) 
which was significantly different from LAI (Figure 2.4 A, 3.03 + 0.54 (n = 7); p = 0.0242).  
Similarly, in Figure 2.4 C, the average peak viral load for LAINeffsΔ-13 was lower than LAI 
(0.93 + 0.23 (n = 4); p = 0.0061). Thus, there appears to be about a threefold reduction in peak 
viral load relative to wild type for LAINeffsΔ-1 and LAINeffsΔ-13.  
 During infection with LAI, CD4+ T cell levels in blood were dramatically reduced 
(Figure 2.4 B and D) while CD4+ T cells in the blood of uninfected mice were maintained at 
approximately 80% of total blood T cells (Figure 2.4 B and D). For LAI, the average time to 
reduce CD4+ T cells to 50% of total blood T cells was 21.6 + 2.4 days post infection (dpi, n = 7). 
For mice inoculated with LAINeffsΔ-1 or LAINeffsΔ-13, an intermediate loss of CD4+ T cells 
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was evident (Figure 2.4 B and D).  The time for CD4+ T cells in blood to decline to 50% of total 
T cells was determined and compared to LAI (Figure 2.4 B and D). As noted, LAI gave 21.6 + 
2.4 dpi (n = 7), which was significantly shorter than LAINeffsΔ-1 at 65.1 + 13.4 dpi (n = 4, p = 
0.0106) and LAINeffsΔ-13 at 52.5 + 13.5 dpi (n = 4, p = 0.0294). LAINeffsΔ-1 and LAINeffsΔ-
13 infected mice were not statistically different from each other. Together, the results from 
Figure 2.4 document an intermediate in vivo Nef phenotype for LAINeffsΔ-1 and LAINeffsΔ-13.  
 We have previously reported the phenotypes of LAI and LAI with a totally inactivated 
nef (LAINefdd, [60]).  The observation that LAI expressing a Nef specifically defective for CD4 
downregulation has a significant level of replication and cytotoxicity was not expected based on 
previous reports [150, 171, 210].  In support of our conclusion, we also noted that a partial loss 
of CD4+ T cells from blood is established by six weeks. At this time point, the percent of CD4+ T 
cells in LAINeffsΔ-1 and LAINeffsΔ-13 infected mice were significantly lower than in Naïve 
mice but significantly higher than in LAI-infected mice (Figure 2.4 B and D).  For LAINeffsΔ-1 
inoculated mice, the percent CD4+ T cells of total T cells present in blood was 55.4 + 3.3 (n = 4) 
compared to 77.5 + 2.8 (n = 4) for Naïve (Figure 2.4 B) with p = 0.0286. For LAINeffsΔ-13 
inoculated mice, the percentages were 47.0 + 11.7 (n = 4) versus 77.5 + 2.8 (n = 4) with p = 
0.0286. Also at six weeks, LAINeffsΔ-1 and LAINeffsΔ-13 infected mice had higher percentages 
of CD4+ T cells than LAI infected mice (Figure 2.4 B and D). Percent of CD4+ T cells for LAI 
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was 12.5 + 4.5 (n = 6), versus 55.4 + 3.3 (n = 4, p = 0.0095) for LAINeffsΔ-1. Percent of CD4+ T 
cells for LAI versus LAINeffsΔ-13 was 12.5 + 4.5 (n = 6) versus 47.0 + 11.7 (n = 4, p = 0.0190).  
 At eight weeks, CD4+ T cells in blood of LAI infected mice are nearly depleted while 
Naïve mice maintained CD4+ T cells at approximately 80% of total CD4+ T cells  (Figure 2.4 B 
and D, [60, 198]).  It was of interest to allow the LAINeffsΔ-1 and LAINeffsΔ-13 infections to 
continue past eight weeks to determine if these viruses would slowly deplete CD4+ T cells from 
blood.  By 14 weeks, substantial levels of CD4+ T cells were still evident in blood for both 
viruses, which emphasizes the persistence of the partial Nef phenotype in the absence of CD4 
downregulation (Figure 2.4 B and D).   
2.4.3 Systemic loss of CD4+ T cells in BLT humanized mice infected with LAINeffsΔ-1 and 
LAINeffsΔ-13  
 We previously observed that systemic loss of human CD4+ T cells from organs closely 
paralleled loss of human CD4+ T cells from blood during infection with wild type (LAI) and nef-
defective (LAINefdd) virus [60, 198]. For LAINeffsΔ-1 and LAINeffsΔ-13 infected mice, we 
also determined that the loss of CD4+ T cells in peripheral blood is matched by the loss of these 
cells from bone marrow, lymph node, liver, lung and spleen (Figure 2.5 A). Statistical analysis of 
Naïve versus LAI, LAINeffsΔ-1 and LAINeffsΔ-13 infected mice demonstrated significant 
losses in the percent of CD4+ T cells in the five tissues (fifteen comparisons to Naive, all gave p 
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< 0.05). Also, the fraction of total T cells that were CD4+ was consistently higher in LAINeffsΔ-
1 infected mice compared to LAI (all five comparisons, p < 0.05). In the case of LAINeffsΔ-13 
versus LAI, three of five organs had statistically higher levels of CD4+ T cells in LAINeffsΔ-13 
infected mice, with the higher levels of CD4+ T cells not reaching statistical significance for 
bone marrow and lymph node. The comparisons between LAINeffsΔ-1 and LAINeffsΔ-13 
infected mice were not significantly different in any tissue. Therefore, the partial reduction of 
CD4+ T cells in blood seen with LAINeffsΔ-1 and LAINeffsΔ-13 infection is systemic. 
 We previously reported a devastating impact of LAI infection on CD4+ CD8+ 
thymocytes. However, LAI lacking a functional nef failed to reduce double positive thymocytes 
[60]. In Figure 5B, drastic depletion of CD4+ CD8+ thymocytes was confirmed following 
inoculation with LAI.  Intermediate losses were observed with LAINeffsΔ-1 and LAINeffsΔ-13 
(Naive, 76.3 + 3.0%; LAI, 1.7 + 1.2%; LAINeffsΔ-1, 35.0 + 17.1%; LAINeffsΔ-13, 29.3 + 
10.2%). On the basis of the above results, we conclude that the partial losses of LAINeffsΔ-1 and 
LAINeffsΔ-13 found for CD4+ T cells appeared to extend to CD4+ CD8+ thymocytes as well.   
 The mechanistic interpretation of the intermediate phenotype of the LAINeffsΔ-1 and 
LAINeffsΔ-13 viruses depends on the status of the sequence of nef. We sequenced nef in plasma 
virion RNA of LAINeffsΔ-1 and LAINeffsΔ-13 and found no reversions over the course of 
infection.  Specifically, for LAINeffsΔ-1, the four base insertion and the Δ-1 deletion remained 
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intact.  For LAINeffsΔ-13, the four base insertion and the thirteen base deletion remained intact. 
There were no second site mutations present in nef either (not shown). The absence of wild type 
nef sequence from LAINeffsΔ-1 and LAINeffsΔ-13 infected BLT mice implies the stability of 
the phenotypic properties of these two nefs during infection.  This failure of nefs from 
LAINeffsΔ-1 and LAINeffsΔ-13 to revert to wild type supports the hypothesis that the 
appearance of wild type nef sequence found in four of seven mice (Figure 2.2) infected with 
LAINeffs was the result of an exact four base deletion and not a two-step removal of the four 
base insertion plus a one base addition.  Therefore, our investigations of LAINeffsΔ-1 and 
LAINeffsΔ-13 demonstrate that LAIs stably lacking Nef’s CD4 downregulation activity have the 
in vivo phenotype of a reduced capacity for viral replication, for CD4+ T cell depletion and for 
CD4+ CD8+ thymocyte depletion relative to LAI [60]. 
2.4.4 LAI, LAINeffsΔ-1 and LAINeffsΔ-13 and systemic T cell activation  
 One explanation for the intermediate infection phenotypes of LAINeffsΔ-1 and 
LAINeffsΔ-13 would be an inability of these mutated HIV-1s to induce systemic T cell 
activation [211, 212].  It has been previously reported that naïve BLT mice have approximately 
2% of CD8+ T cells that are CD38+ HLA-DR+ double positive in blood. Infection with LAI or 
LAINefdd elevates this fraction to approximately 8% [60, 186]. We observed similar effects of 
LAINeffsΔ-1 and LAINeffsΔ-13 infection on T cell activation. At six weeks post infection, 
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LAINeffsΔ-1 and LAINeffsΔ-13 were determined to have 8.2 + 3.5 % (n = 4) and 6.1 + 2.3 % (n 
= 4) CD38+ HLA-DR+ double positive CD8+ T cells in blood, respectively. Thus, LAINeffsΔ-1 
and LAINeffsΔ-13 exhibit the same enhancements of peripheral blood T cell activation as LAI 
and LAINefdd.  
2.4.5 The role of SH3 domain dependent activities on LAI infection of BLT mice  
 A large number of diverse activities of Nef have been shown to be dependent on the 
highly conserved SH3 domain-binding site. We considered the possibility that these activities 
may account for the observed selective advantage of the LAINeffsΔ-1 and LAINeffsΔ-13 over 
LAINeffs despite the absence the CD4 downregulation activity. SH3 domain-binding dependent 
activities are blocked by mutating two key prolines in Nef’s polyproline helix (P72A/P75A, 
[124, 173]). To investigate the role of the P72A/P75A mutant Nef in vivo we generated isogenic, 
replication competent LAINefP72A/P75A.  In 293T cells, LAINefP72A/P75A expressed similar 
levels of Nef and p24gag compared to LAI (Figure 2.6 A) and actively replicated in A3.01 T cells 
(Figure 2.6 B).  We assayed the enhancement of virion infectivity for LAI and 
LAINefP72A/P75A and observed the expected loss of this activity for the SH3 domain binding 
site mutant (Figure 2.6 C, [93, 127, 134]).  Also, we expressed the mutated nef from 
LAINefP72A/P75A with the retroviral vector, LXSN, in CEM T cells and found it to be 
functional for CD4 downregulation but consistent with previous reports largely defective for 
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MHCI downregulation (Figure 2.6 D [84, 98, 179]). On the basis of these results, we concluded 
that infecting BLT mice with LAINefP72A/P75A would distinguish between the phenotypic 
impacts of SH3 domain binding protein dependent activities and CD4 downregulation.  
 BLT mice were infected with 90,000 TCIU of LAINefP72A/P75A mutant virus (Figure 
2.7). Under these experimental conditions, a 1.9-fold higher peak viral load was observed for 
LAINefP72A/P75A versus LAI (Figure 2.7 A). This difference was not statistically different 
(5.83 + 1.84 (n = 4) versus 3.03 + 0.54 (n = 7); p = 0.1091). In addition, the P72A/P75A Nef 
mutant and the wild type virus showed a similar time course for reduction of peripheral blood 
CD4+ T cells to 50% of total T cells in blood with LAINefP72A/P75A at 29.5 + 4.1 dpi (n = 4) 
versus LAI at 21.6 + 2.4 dpi (n = 7); p = 0.1554 (Figure 2.7 B).  These results indicate that a 
functional SH3 domain-binding site in Nef is not required in vivo for either high levels of virus 
replication or for CD4+ T cell depletion. 
2.4.6 Systemic depeltion of CD4+ T cells and thymocytes by LAINefP72A/P75A  
 In transgenic mice, it has been reported that expression of HIV-1 Nef from a CD4 
promoter is cytotoxic to CD4+ T cells in multiple organs [64].  In addition, this cytotoxic effect is 
lost when the polyproline helix is mutated [177]. Therefore, we determined the impact 
LAINefP72A/P75A infection in BLT mice on CD4+ T cells in bone marrow, lymph node, liver, 
lung and spleen (Figure 2.8 A). LAI and LAINefP72A/P75A effectively depleted CD4+ T cells. 
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All differences in levels of CD4+ T cells between Naïve mice and either LAI or 
LAINefP72A/P75A mice are statistically significant. In contrast, comparisons between the levels 
of residual CD4+ T cells in mice infected with LAI versus LAINefP72A/P75A were not 
significantly different (Figure 2.8 A).  CD4+ CD8+ thymocytes in the human thymic organoid 
were also analyzed.  We found that these cells were efficiently depleted by LAINefP72A/P75A 
(Figure 2.8 B). We, therefore, conclude that contrary to expectations the mutation, P72A/P75A 
has little to no effect on the systemic depletion of CD4+ T cells or CD4+ CD8+ thymocytes in 
vivo.  
2.4.7 In vivo selection pressure to correct the P72A/P75A mutation is weak  
 Our conclusion that an intact SH3 domain-binding site is not a major factor in 
determining the level of HIV-1 replication suggests that there is little or no selection pressure for 
reversion of the alanines to prolines.  LAINefP72A/P75A virion RNA from plasma of the 
LAINefP72A/P75A infected mice from Figures 2.7 and 2.8 was processed for sequencing.  No 
nucleotide changes in nef were noted through six weeks for the entire nef sequence from all four 
mice.  Also, no changes were seen to fourteen weeks for three of four mice (not shown). At week 
eight, however, nef sequence from one of the four mice infected with the P72A/P75A mutant 
virus had a clear shift from guanine to mostly cytosine at the first base of the codon for position 
75 (Figure 2.9).  This transversion converted the mutant alanine codon (GCT) to the wild type 
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proline codon (CCT).  Even though the CD4+ T cells in LAINefP72A/P75A infected mice were 
nearly depleted, we continued monitoring the infection past eight weeks to determine if further 
mutations would occur during LAINefP72A/P75A infection. Interestingly, for the mouse 
presented in Figure 2.9, the virus with an alanine codon at 72 and proline codon at 75 completely 
replaced the input virus but failed to revert the alanine codon at position 72 (Figure 2.9, Weeks 
10-14).  There were no other changes in the nef sequence from this mouse (not shown). Since no 
reversion to original SH3 domain binding site (P72/P75) occurred within the eight week time 
frame, the high levels of viral replication and peripheral blood CD4+ T cell depletion could not 
be explained by appearance of wild type virus. However, it should be noted that in vitro studies 
have documented an intermediate MHC1 downregulation activity for the proline 75 mutation 
[93]. Thus, our results support a model where CD4 downregulation plus one or a few additional 
activities- not dependent on the SH3 domain binding site- largely account for Nef’s impact on 
viral replication and/or pathogenesis. Loss of the capacity for SH3 domain binding has little 
effect on viral replication and pathogenesis and exhibits at best a small reduction in viral fitness. 
2.5 Discussion  
 Previously, we established that there are large phenotypic differences between infection 
of BLT mice with wild type LAI and the nef-defective LAINefdd in vivo [60]. LAI replicates to 
high viral loads concomitantly with aggressive and systematic depletion of CD4+ T cells and 
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CD4+ CD8+ thymocytes.  LAINefdd exhibits 6-7 fold lower peak viral loads and has little to no 
capacity to deplete CD4+ T cells or thymocytes [60].  These two large effects of Nef make it 
feasible to characterize the importance of Nef’s individual activities in BLT mice [162]. Here, 
we have demonstrated a third important property of nef in the BLT mouse model- the ability to 
evolve and restore functionality.  Viruses expressing Nef proteins have a decisive replicative 
advantage over the frame-shifted LAINeffs and replace the nef-defective virus within a few 
weeks. Hence, in seven mice, the input LAINeffs was lost after four weeks with either 
LAINeffsΔ-1 (six mice) or LAINeffsΔ-13 (one mouse) being the sole virus in peripheral blood.  
By eight weeks, four of seven mice further evolved to be predominantly wild type virus.  
 The strong in vivo selection of LAINeffsΔ-1 and LAINeffsΔ-13 over LAINeffs led us to 
characterize these in vivo selected mutant proteins in vitro. We discovered them to be stable but 
with a total loss of CD4 downregulation activity. Three other in vitro Nef activities, MHCI 
downregulation, PAK2 activation and enhancement of virion infectivity, remained intact. When 
BLT mice are infected with LAINeffsΔ-1 and LAINeffsΔ-13, we observed an approximate 3-
fold reduction in peak viral load and a partial loss of CD4+ T cells and CD4+ CD8+ thymocytes 
relative to that observed for LAI. These observations suggest that the in vivo selection of the two 
viruses with mutant nefs relative to LAINeffs relied on activities beyond CD4 downregulation.  
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Conversely, the partial reduction of Nef effectiveness observed for LAINeffsΔ-1 and LAINeffsΔ-
13 demonstrates a significant role for CD4 downregulation.  
 Our data provided evidence that there is selective pressure for restoration of Nef activities 
other than CD4 downregulation. The identity of these activities is unknown. We considered 
likely candidates to be one or more of the SH3 domain binding site dependent activities. These 
activities include enhancement of virion infectivity [93, 127, 134], PAK2 activation [93, 173, 
174], upregulation of Fas ligand (FasL) and programmed cell death 1 (PD1) [155, 156], 
activation of  Hck [144], downregulation of MHCI [84, 179, 180] and Lck-dependent activation 
Ras-Erk signaling to promote the production of the T lymphocyte survival factor IL-2 [158, 213]. 
We mutated prolines 72 and 75 to alanine to prevent interactions between Nef and host cell SH3 
domain proteins [93, 173]. This mutation did not exhibit a negative effect on Nef function in 
BLT mice. One explanation for this counter intuitive observation is that high levels of replication 
and rapid reduction in CD4+ T cell and CD4+ CD8+ thymocytes depend on only a few Nef 
activities.  
 Future studies with BLT mice will investigate Nef activities that are potentially 
responsible for the CD4 downregulation-independent aspects of Nef function in vivo.  Possible 
activities include elevated secretion of exosomes, blocking the anti-viral effect of autophagy and 
inhibition of ASK1 [71, 214-218].  Conversely, these studies may lead to the important result 
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that known Nef activities may not account for a substantial portion of its impact on HIV-1 
infection in vivo [219].  In this regard, our mutational strategy of introducing palindromic 
insertions into Nef coding sequence can be extended to scan the protein for regions of special 
significance for viral replication and pathogenesis.  The HIV-1/BLT mice infection model 
described here is a feasible experimental platform for resolving these questions.
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Figure 2.1. A frame shift in nef ablates expression of Nef but does not affect viral replication.  
(A) Upper Panel, Left, Schematic representation of wild type LAI (WT LAI) is presented. 
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Nucleotides 8390 to 9010 in NCBI accession number, K02013, represent the nef coding 
sequence. Lower Panel, Left, A schematic of frame shifted nef (LAINeffs) is presented. The 
insertion of GATC following nucleotide 8494 is indicated. PPT, polypurine tract. Upper Panel, 
Right, Flow chart describing the generation of the GATC insertion is presented. (B) The frame 
shift in nef eliminates Nef expression but does not alter the expression of Gag. nef (α-Nef) and 
gag (α -p24) encoded proteins were detected by Western blot analysis of 293T producer cell 
lysates.  GAPDH (α -GAPDH) is a protein loading control. (C) A3.01 cells were infected with 
LAI or LAINeffs at a multiplicity of infection of 0.05 and viral production was followed for 20 
days with ELISA for p24gag. 
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Figure 2.2. LAINeffs mutates to have one of three nefs with an open reading frame.  (A) At 
several time points during the eight week infection, viral RNA was reverse transcribed from 
plasma. After amplification by PCR, nef was sequenced.  By four weeks, six of seven mice 
exhibited nef sequence with a one base deletion just downstream of the four base insertion in a 
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run of five adenines.  This one base deletion (Δ-1) restored the nef reading frame.  In the 
remaining mouse, a 13 base deletion occurred downstream of the four base insertion (Δ -13) 
which also restored the nef open reading frame.  Three of the seven mice had a mixture of two 
different sequences in plasma which are indicated by the “majority sequence / the minority 
sequence.” By seven weeks, there were two mice with reversions to wild type sequence (WT) by 
the removal of four inserted bases from CTCGATCGAG to yield CTCGAG.  +4, nef with the 
original four base insertion intact. (B) The conceptual translations of the LAINeffs Δ -1 and 
LAINeffsΔ-13 mutated nefs are aligned with wild type LAI Nef amino acid sequence.  Bold 
indicates missense amino acids encoded by LAINeffs Δ -1 and LAINeffs Δ -13. 
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Figure 2.3. LAINeffsΔ−1 and LAINeffsΔ−13 encode Nefs that are specifically defective for 
downregulating surface expression of CD4. (A) Nefs encoded by LAINeffs Δ-1, LAINeffs Δ-13 
and LAI were expressed in CEM cells following transduction with retroviral vectors (LXSN). 
Upper Panel, A Western blot demonstrates LAI Neffs Δ-1 and LAI Neffs Δ-13 were expressed at 
comparable levels as wild type (α-Nef). LXSN and LXSNNeffs served as negative controls.  
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GAPDH is a protein loading control (α -GAPDH).  Lower Panel, CEM cells expressing LAI 
Nef, LAI Neffs, LAI Neffs Δ -1 and LAI Neffs Δ -13 were analyzed by flow cytometry for cell 
surface CD4 and MHC Class I (MHCI) expression. LXSNLAINef was the positive control. 
LXSN and LXSNLAINeffs were negative controls.  LAI NeffsΔ-1 and LAI NeffsΔ-13 were fully 
defective for CD4 downregulation but functional for MHCI downregulation.  Percentage of cells 
in each quadrant out of total cells is indicated.  (B) Nefs encoded by LAI, LAINeffsΔ-1 and 
LAINeffsΔ-13 were expressed in transfected 293T cells. Control, 293T cells transfected with 
empty vector. Upper Panel, Lysates from transfected cells were analyzed by Western blot and 
comparable expression of the three Nefs was observed (α-Nef). Lower Panel, Total p21 
activated protein kinase-2 (PAK2) in lysates of transfected cells lysates were 
immunoprecipitated with anti-PAK2 antiserum (α-PAK2) and analyzed by the in vitro kinase 
assay (IVKA).  Control cells with no Nef expression had no activated PAK2.  Arrow, 
autophosphorylated PAK2.   (C) pLAI, pLAINeffs, pLAINeffsΔ-1 and pLAINeffsΔ-13 proviral 
clones were transfected into 293T cells and virus harvested from the media.  LAI, LAINeffs, 
LAINeffsΔ-1 and LAINeffsΔ-13 were titered using HeLa-MAGI indicator cells [204] and p24gag 
contents were quantified by ELISA.  Infectivities (blue cells per ng p24gag) from six 
determinations of each virus were normalized relative to LAI (100%).  Significant comparisons  
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are indicated by lines and arrows above respective bars (*, p < 0.05). (D) A3.01 cells were 
infected with LAI, LAINeffsΔ-1 and LAINeffsΔ-13 at multiplicity of infection of 0.05 and viral 
production followed for 20 days with ELISA for p24gag. 
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Figure 2.4. Viral load analysis and peripheral blood CD4+ T cell depletion in mice infected with 
LAI.  (A) Viral loads (copies of LAI RNA per milliliter of plasma) of BLT humanized mice 
exposed to 90,000 TCIU of LAI or LAINeffsΔ-1 were plotted. Uninfected mice (Naïve) served 
as negative controls (open circle, n = 8); LAI (filled circle, n=7); and LAINeffsΔ-1 (filled square, 
n = 4). (B) Plot of percent peripheral blood CD3+ T cells expressing CD4. Naïve mice, LAI and 
LAINeffsΔ-1 as in (A). (C) Viral loads were plotted following inoculation of 90,000  
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TCIU of LAI or LAINeffsΔ-13. Naïve mice as negative controls (open circle, n = 8); LAI (filled 
circle, n=7); and LAINeffsΔ-13 (filled triangles, n = 4). (D) Plot of percent peripheral blood 
CD3+ T cells expressing CD4. Naïve mice, LAI and LAINeffsΔ-13 as in (C). 
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Figure 2.5. Analysis of CD4+ T cells from tissues in mice exposed to LAI, LAINeffsΔ−1 or 
LAINeffsΔ−13.  (A) Percent CD4+ T cells of total T cells in five organs from unexposed BLT 
mice (Naive, n = 8) were compared to groups of BLT mice exposed to one of three viruses: LAI 
(n = 6), LAINeffsΔ-1 (n = 4), or LAINeffsΔ-13 (n = 4). Statistical comparisons reaching 
significance are indicated by lines and arrows above respective bars (*, p < 0.05). (B) The same 
groups as in (A) were compared for CD4+CD8+ double positive thymocytes relative to total 
thymocytes. 
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Figure 2.6. LAINefP72A/P75A replicates in A3.01 T cells and is functional for CD4 
downregulation.  pLAI, pLAINeffs and pLAINefP72A/P75A proviral clones were transfected 
 61 
into 293T cells and virus harvested from the media. (A) Nef (α-Nef) and p24gag (α-p24) proteins 
were detected by Western blot analysis of 293T producer cell lysates. Control is non-transfected 
293T cells. GAPDH (α-GAPDH) is a protein loading control. (B) A3.01 cells were infected with 
LAI and LAINefP72A/P75A at multiplicity of infection of 0.05 and viral production followed 
for 20 days with ELISA for p24gag. (C) LAI, LAINeffs and pLAINefP72A/P75A were titered 
using HeLa-MAGI indicator cells [204] and p24gag quantitated by ELISA. Infectivities were 
normalized to LAI (100%).  (D) Nefs encoded by LAINefP72A/P75A and LAI were expressed 
in CEM cells following transduction with retroviral vectors (LXSN). CEM cells expressing LAI 
Nef and LAI NefP72A/P75A were analyzed by flow cytometry for cell surface CD4 and MHC 
Class I expression.  LXSN is the negative control. Percentage of cells in each quadrant out of 
total cells indicated. 
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Figure 2.7. Viral load analysis and peripheral blood CD4+ T cell depletion in mice infected with 
LAINefP72A/P75A.  (A) Viral loads of BLT mice were plotted for BLT humanized mice that 
were exposed to 90,000 TCIU of LAI (n = 7) and LAINefP72A/P75A (n = 4). Uninfected mice 
(Naïve) served as negative controls.  (B) The percent of CD4+ T cells out of total T cells in 
peripheral blood are plotted for mice in (A). 
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Figure 2.8. Analysis of CD4+ T cells from tissues from mice exposed to LAI or 
LAINefP72A/P75A.  (A) Percent of CD4+ T cells out of total T cells from bone marrow, lymph 
node, liver, lung and spleen from unexposed BLT mice (Naive, n = 8) were compared to groups 
of BLT mice exposed to LAI (n = 7) or LAINefP72A/P75A (n = 4).  Statistical comparisons 
reaching significance are indicated by lines and arrows above respective bars (*, p < 0.05).  (B) 
The same analysis as in (A) is presented for CD4+CD8+ double positive thymocytes relative to 
total thymocytes. Statistical comparisons reaching significance are indicated by lines and arrows 
above respective bars (*, p < 0.05). 
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Figure 2.9. Delayed partial reversion of P72A/P75A.  nef sequences were obtained from viral 
RNA in plasma of four LAINefP72A/P75A infected mice from Figure 2.7.  Only one of four 
mice had a change in nef sequence which is shown in the panels here.  This was the reversion of 
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the P75A mutation back to proline. The delayed and limited appearance of this mutation may be 
the result of the low probability of a transversion (G to C) coupled to a small enhancement of 
viral fitness. The twelve nucleotides encoding the SH3 domain binding motif core 
(P72Q73V74P75) are presented. The wild type proline codons that were mutated to alanine are 
P72A (left panel headed by GCT) and P75A (right panel headed by GCT). The replacement of 
guanine with cytosine that restores the P75 codon is seen in the right panels of weeks 8, 10, 12 
and 14 headed with CCT instead of GCT.  Arrow, guanine mutated to cytodine. A, green; C, 
blue; G, black: T, red. The four codons presented are GCT, alanine; CCT, proline; CAG, 
glutamine; GTA, valine. 
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CHAPTER 3: THE HIV-1 ACCESSORY PROTEIN, VPU, IS A MAJOR PATHOGENICITY 
FACTOR2 
3.1 Summary 
Background  
 Vpu is a multifunctional HIV-1 accessory protein that down-regulates two cellular 
antagonists of HIV-1, tetherin and CD4. Vpu may also facilitate sexual transmission and 
accelerate the epidemic spread of HIV-1 Group M.   
Results 
 We employed BLT mice containing a humanized immune system to investigate the 
effects of Vpu on HIV-1 infection. A role for Vpu in pathogenesis has remained undefined.  
Intravenous injection of BLT mice with pathogenic CXCR4-tropic virus, HIV-1LAI (LAI) or LAI 
with a deletion in vpu (LAIΔvpu, 0.56 ng p24gag) revealed an attenuated pathogenic phenotype 
for LAIΔvpu.  LAIΔvpu reduced levels of CD4+CD8+ cells in human thymus and CD4+ T cells in 
blood and tissues by 60% compared to >90% depletion for LAI.  LAIΔvpu exhibited a 4.4-fold 
lower peak viral load relative to LAI. 
 
 
2 Richard L Watkins, John F Krisko, John L Foster and J Victor Garcia. The HIV-1 Accessory 
Protein, Vpu, is a Major Pathogenicity Factor. RW, JK, and JF performed experiments 
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  Conclusion 
 We concluded that Vpu is important for full CD4+ T cell cytotoxicity and robust 
replication.  
3.2 Introduction  
 The HIV-1 accessory protein Vpu counters the INFα-induced tethering of virions to the 
surface of the infected cell [220].  Vpu acts by neutralizing the membrane protein tetherin, which 
mediates this block in virus release [221, 222].  However, in chimpanzee, and nearly all simian 
immumodeficiency viruses, it is Nef not Vpu that blocks the inhibition of virus release by 
tetherin [223-228].  In the case of HIV-1 Group M, anti-tetherin activity resides solely in Vpu [8, 
224, 226].  Group M (but not Groups N, O, or P) vpu acquired the capacity to down-regulate 
tetherin after zoonotic transfer from chimpanzees since SIVCPZ Nef is ineffective against human 
tetherin [222, 229-231].  Based on in vitro studies of Group M, N, O and P Vpu’s, it has been 
proposed that HIV-1 Group M  vpu’s antitetherin activity may greatly enhance transmission 
resulting in the spread of HIV-1 Group M virus to epidemic proportions [8, 223, 226, 232, 233].  
Therefore, it is expected that without Vpu expression, early viral propagation leading to systemic 
infection would be attenuated in vivo [8, 221, 224, 226, 230].  Unfortunately, direct experimental 
evidence for this hypothesis is lacking.  Indeed, Dave et al. [234] and Sato et al. [235] that found 
intraperitoneal injection of low inoculums of vpu- virus established systemic infections in mice 
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with humanized immune systems at an efficiency not statistically different from wild type vpu+ 
virus. 
 Some investigators consider tetherin to be an HIV-1 restriction factor based on its 
capacity to prevent virion release from infected cells [236-238].   Other investigators have 
suggested a complex phenotype for tetherin even including situations in which tetherin 
expression is a positive factor for HIV-1 replication [239, 240]. One scenario for enhancement of 
viral replication by tetherin is during cell to cell spread though this effect remains controversial 
[238].  It has also been suggested that tetherin serves as a cellular signal of viral infection leading 
to NFκ-B activation [241, 242]. By down-regulating tetherin, Vpu may neutralize this signal 
[241-246].   
 Vpu is also known to retain and then direct the degradation of CD4 in the ER [154].  This 
Vpu activity is thought to be important to prevent the binding of CD4 to Env within the infected 
cell prior to virion budding [247].  Delivery of CD4-free Env to the virion surface allows the 
interaction of Env with HIV-1 receptors on new target cells [147, 246, 248, 249].  The 
importance of this Vpu activity for viral replication and pathogenesis is not known but it has 
been shown in SCID-hu mice and human lymphoid tissue ex vivo that Vpu expression is 
necessary for wild type levels of replication and pathogenesis [250, 251]. 
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 To address the significance of Vpu in HIV-1 infection, we have infected bone marrow 
liver thymus mice (BLT, [252]) humanized mice with wild type or vpu- HIV-1 by intravenous 
inoculation with CXCR4-tropic HIV-1LAI (LAI) and LAI with a large deletion in vpu.  We have 
then determined the in vivo effects of Vpu on viral replication, CD4+ T cell loss, thymocyte loss 
and systemic T cell activation.    
3.3 Experimental Procedures 
3.3.1 BLT humanized mice  
 The mice were individually bioengineered by bone marrow transplant of CD34+ 
hematopoietic progenitor cells into immunodeficient mice previously implanted with autologous 
liver and thymus tissue [184, 196, 203].  Briefly, NOD/SCID- IL-2γ-/- mice (NSG, The Jackson 
Laboratories, Bar Harbor, ME) implanted with thymus and liver tissue (Advanced Bioscience 
Resources, Alameda, CA) were irradiated and subsequently transplanted with 3.5X105 
autologous fetal liver CD34+ cells and monitored for human engraftment.  Human reconstitution 
in the peripheral blood of these mice was monitored by flow cytometry (FACSCanto; BD 
Biosciences).  Mice were maintained at the Division of Laboratory Animal Medicine at the 
University of North Carolina at Chapel Hill (UNC-CH) in accordance with protocols approved 
by the Institutional Animal Care and Use Committee. To ensure genetic diversity, twenty-five 
different tissue donors were used to generate the groups of mice used for the experiments 
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presented in this manuscript. The overall level of engraftment for all the mice used in this 
manuscript was 63.5% ±2.4% (mean ±SEM, n = 56) with an interquartile range of 54.0% to 
75.0%.  
3.3.2 Proviral Clones   
 To generate vpu(-) virus, we introduced a 71 base pair deletion by by a site-directed 
mutagenesis strategy (QuickChange II Site-Directed Mutagenesis kit, Stratagene) into the HIV-
1LAI (LAI, K02013) proviral clone (JRCSF, M38429).  The deletion in LAIΔvpu (nucleotides 
5656-5723, inclusive) was in the 5’ end of vpu coding sequence just downstream of the vpu 
initiation codon.  
3.3.3 Virus production and titering   
 Stocks of LAI, and LAIΔvpu were prepared by transient transfection of 293T cells as 
previously described [200, 201].  Briefly, proviral clones were transfected into 293T cells, viral 
supernatant was collected 48 hours after transfection and concentrated by ultracentrifugation.  
Then viral titers in tissue culture infectious units (TCIU) were determined by the β-galactosidase 
TZM-bl cell assay as previously described [60, 185].  TZM-bl cells were infected in 12-well 
tissue culture plates with 0.4 ml of virus-containing medium for two hours.  Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 100 IU penicillin/ml, 100 
mg/ml streptomycin, and 2 mM glutamine (1.0 ml) was added, and the plates incubated 
 71 
overnight.  Virus-containing medium was removed the next day and the incubation was 
continued for 24 hours.  The cells were fixed and stained (40 hours after first virus exposure).  
The titers of these viral stocks were determined in triplicate and at least two different titer 
determinations were performed in each batch of virus used for all the experiments described in 
this manuscript.  The p24gag content of the viral stocks and in vitro viral replication assays were 
determined by ELISA. 
3.3.4 Exposure of BLT mice, tissue harvest and flow cytometric analyses   
  Intravenous exposure of BLT mice with LAI or LAIΔvpu (30,000 TCIU) was conducted 
via tail vein injection as previously described [60, 191].   
 Infection of BLT mice with HIV was monitored in plasma by determining levels of viral 
RNA using one-step reverse transcriptase real-time PCR (ABI custom TaqMan Assays-by-
Design) according to the manufacturer’s instructions [primers (5’-
CATGTTTTCAGCATTATCAGAAGGA-3’) and (5’-TGCTTGATGTCCCCCCACT-3’) and 
MGB-probe 5’FAM-CCACCCCACAAGATTTAAA CACCATGCTAA-Q 3’] as previously 
described [193, 202].  
 Flow cytometric analyses were performed on blood samples collected longitudinally and 
mononuclear cells isolated from tissues at harvest.  Peripheral blood from BLT mice was 
analyzed according to the BD Bioscience Lyse/Wash protocol (Cat. No. 349202) as we have 
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previously described [185, 196, 198].  Briefly, following antibody labeling of whole blood, red 
blood cells were lysed. The remaining cells were washed, fixed and samples were analyzed by 
flow cytometry.  Tissue mononuclear cell isolations and immuno-phenotyping analyses were 
also performed according to our published methods [60, 185, 193].    
 Flow cytometric data collection and analyses were performed on BD FACS Canto 
cytometer operated using FACSDiva software (V.5.0.3).  Two flow cytometry antibody panels 
were used to analyze peripheral blood and cells isolated from tissues of BLT mice: Panel A - 
CD3 FITC (HIT3a), CD4 PE (RPA-T4), CD8 PerCP (SK1) and CD45 APC (HI30) and panel B 
– CD8 FITC (SK1), HLA-DR, PE (TU36) or IgG2bκ PE, CD4 PerCP (SK3), CD3 PE-Cy7 
(SK7), CD38 APC (HB7) or IgG1 APC, and CD45 APC-Cy7 (2D1) (all purchased from BD 
Biosciences).  Gating for all samples was performed as follows: (step 1) forward and side scatter 
properties were utilized to set a live cell gate; (step 2) live cells were then analyzed for 
expression of the human pan-leukocyte marker CD45; (step 3) human leukocytes were then 
analyzed for CD3, CD4 and/or CD8 expression 
3.3.5 Sequence analyses of plasma virions   
 Sequence of vpu and nef was obtained from plasma virion RNA.  HIV-RNA was 
extracted from 20 µl of plasma from infected mice using the QIAamp Viral RNA Mini kit 
(Qiagen Sciences, USA).  RNA was then reverse transcribed into cDNA, which was subject to 
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nested PCR.  The outer primers for vpu amplification are: 5′-
GTCAGCCTAAGACTGCTTGTACC-3′ and 5′-GTGGGTACACAGGCATGTGTGG-3 and the 
inner primers are:  5′-GACAGCGACGAAGACCTCCTC-3′ and 5′-
GATGCACAAAATAGAGTGGTGG-3′. The outer primers for nef amplification are: 5′-
GAATAGTGCTGTTAGCTTGC-3′ and 5′-CTCAAGGCAAGCTTTATTGAG G-3′ and the 
inner primers are 5′-TAGAGCTATTCGCCACATACC -3′ and 5′-
CTTTATTGAGGCTTAAGCAGT GG -3′.  Gel purified PCR products were sequenced and the 
sequences aligned to LAIΔvpu sequences to determine if sequence changes had occurred. 
3.3.6 Viral Replication in vitro   
 The human T-cell line, CEM-SS (NIH AIDS Reagent Program), was modified to express 
CCR5 [207].  These cells were used to propagate LAI and LAIΔvpu.  Cells were infected with 
virus stocks at a multiplicity of infection (MOI) of 0.05 in complete RPMI (10% fetal bovine 
serum (Hyclone), 50 IU of penicillin per ml, 50 µg streptomycin per ml, 2 mM L-glutamine, and 
1 mM sodium pyruvate) containing 2 µg/ml polybrene at 37o C, 5% CO2 for 4 hours.  The cells 
were washed extensively with PBS and cultured at 37o C, 5% CO2 in complete RPMI.  Cell 
cultures were passaged twice weekly at which time a sample of the culture supernatant was 
collected for quantification of viral capsid protein by p24gag ELISA.  
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3.3.7 Analysis of p55gag and gp120env expression from LAI and LAIΔvpu   
 Lysates from 293T cells transfected with proviral clones were analyzed for protein 
expression by Western blot. p55gag was detected with anti-p24gag (anti-HIV-1 p24 Gag 
Monoclonal, NIH AIDS Reagent Program) and gp120env was detected with anti-HIV-1 gp120 
(HIV-1 gp120 antibody, Fitzgerald Industries International).  
3.3.8 Statistical analyses  
  Bivariate statistical comparisons were performed using Mann-Whitney tests (Prism v5.0, 
Graph Pad). Data presented as mean +SEM.  
3.4 Results 
3.4.1 Vpu and HIV-1 pathogenicity   
 In the pigtail macaque infection model, vpu is critical for the extreme pathogenicity of the 
CXCR4-tropic SHIV4 [253-256].  In contrast, HIV-1 Group N virus is pathogenic even though, 
in general, Group N Vpu’s are minimally functional for CD4 down-regulation and tetherin 
antagonism [257, 258]. Further, infection of BLT mice with the CCR5 tropic viruses, made 
investigating of a possible role of Vpu in pathogenesis difficult, as these viruses are weakly 
pathogenic [234, 235].  Therefore, we tested the highly pathogenic CXCR4-tropic HIV-1LAI 
(LAI) for possible Vpu dependence as LAI Vpu has been shown to be functional for CD4 and 
tetherin down-regulation [60, 223].  LAI containing a 68 base deletion in vpu (LAIΔvpu) 
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downstream of its initiation codon and upstream of the env initiation codon was constructed 
(Figure 3.1 A).  LAI and LAIΔvpu expressed similar levels of p55gag and gp120env (Figure 3.1 
B).  The two viruses also replicated similarly in vitro (Figure 3.1 C).  
 BLT mice were inoculated by intravenous injection with LAI or LAIΔvpu (3000 TCIU, 
0.54 ng p24gag).  High levels of viral RNA in plasma were observed at two weeks (Figure 3.2 A).  
In Figures 3.2 B and C, peak viral loads in blood were observed to be reduced 4.4-fold for 
LAIΔvpu (1.09X106 +0.15X106 copies viral RNA/ml, n=3) compared to LAI (4.83X106 
+0.49X106 copies viral RNA/ml, n=5; p=0.0357).  This fold-difference was maintained 
throughout the course of the infection with viral loads at 11 weeks of 0.42X106 +0.09X106, n=3 
for LAIΔvpu and 2.21X106 +0.67X106, n=5 for LAI (p=0.0357, Figure 3.2 A).  Therefore, loss 
of Vpu expression reduces overall viral replication for the CXCR4 tropic LAI by 4 to 5 fold 
compared to a minimal effect on viral replication for CCR5 tropic virus.  
 LAI infection results in massive loss of CD4+ T cells from blood and tissues [60]. In 
Figure 3.3, we monitored the effect of inactivating vpu on CD4+ T cell and CD4+CD8+ 
thymocyte depletion.  As presented in Figure 3.3 A, uninfected mice maintained CD4+ T cells at 
near constant levels, while LAI and LAIΔvpu infected mice exhibited progressive loss of these 
cells. By eight weeks, five LAI infected mice had only 25.9% +8.1% of the level of CD4+ T cells 
in uninfected mice while three JRCSFΔvpu infected mice had 62.3% +8.6% (p=0.0357).  By 
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eleven weeks, the level of CD4+ T cells in LAI infected mice fell by 90% (10.1% +3.2%, n=5) 
while in LAIΔvpu infected mice there was only a partial reduction (41.7% +11.9%, n=3; 
p=0.0357).   
 The different effects of LAI versus LAIΔvpu on CD4+ T cells in peripheral blood were 
reflected in tissues.  In Figure 3.3 B, severe depletion of CD4+ T cells in bone marrow, spleen, 
lymph nodes, liver and lung was found for LAI.  In contrast, LAIΔvpu exhibited an attenuated 
phenotype with CD4+ T cells levels that was intermediate between uninfected mice and LAI 
infected mice in spleen, lymph nodes, liver, and lung (Figure 3.3 B). In bone marrow, LAI and 
LAIΔvpu both reduced CD4+ T cells relative to uninfected mice.  Though LAIΔvpu infected 
BLT mice had higher levels of CD4+ T cells than LAI infected mice this difference was not 
statistically significant (LAI, 16.0% +4.2%, LAIΔvpu, 37.0% +6.8%; p=0.0714). Similar to 
results from spleen, lymph nodes, liver and lung, CD4+CD8+ thymocytes in LAIΔvpu infected 
mice exhibited an intermediate loss between that for uninfected mice and LAI infected mice 
(Figure 3.3 C).  Thus, in five of six tissues, cells susceptible to infection by HIV-1 were present 
at significantly higher levels in LAIΔvpu infected BLT mice than in LAI infected BLT mice 
(Figures 3.3 B and C) but LAIΔvpu infected mice had uniformly lower levels of CD4+ T cells in 
tissues than uninfected mice. Therefore, it appears that Vpu is an important factor for HIV-1 
replication and pathogenesis. 
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 In BLT mice, the overall impact on LAI infection of losing vpu function is qualitatively 
similar but of lesser magnitude compared to loss of nef function [60].  LAI with a defective nef is 
virtually devoid of pathogenic impact.  
3.5 Discussion 
 Prominent defects were observed for the CXCR4-tropic vpu-deleted LAI relative to wild 
type, which establishes Vpu as an important pathogenesis factor (Figure 3.3). In this regard, it is 
of interest to compare LAIΔvpu to nef-deleted LAI (LAIΔnef). We previously reported that peak 
viral loads for BLT mice infected with a low dose of LAIΔnef were reduced 7.1-fold relative to 
wild type LAI while here we found a 4.4-fold reduction when vpu was deleted (Figure 3.2 B, 
[60]).  A greater impact on pathogenesis was also observed with LAIΔnef which failed to deplete 
CD4+ T cells in peripheral blood or in tissues while a partial loss of CD4+ T cells was observed 
with LAIΔvpu (Figure 3.3, [60]).  Also, in contrast to LAI and LAIΔvpu, LAIΔnef had no 
cytotoxic impact on thymocytes [60].  Therefore, it appears that loss of nef has an overall greater 
negative effect on the virus than loss of vpu.  However, it should be noted that the results with 
LAIΔvpu are strikingly similar to our recent report with LAI expressing a Nef that was 
specifically defective for the CD4 down-regulation activity.   With this mutated LAI, we 
observed intermediate reductions in viral replication, in loss of CD4+ T cells and in loss of 
CD4+CD8+ thymocytes [152]. The similarity of the effect of losing Vpu expression and specific 
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loss of the Nef CD4 down-regulation function raises the possibility of a common mechanism.  In 
this scenario, Nef and Vpu would act synergistically to counter the capacity of CD4 to act as a 
major restrictor of viral replication [149, 172, 259]. 
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Figure 3.1. In vitro characterization of HIV-1LAI (LAI) with a 68 base deletion in vpu. (A) 
Schematic representation of LAI vpu with the 68 base deletion indicated (LAI∆vpu) is presented. 
Nucleotides 5643 to 5888 (NCBI accession number, K02013) represent the vpu coding sequence. 
ATG represents the initiation codon of either vpu or env. TAG is the termination codon of vpu. 
The gray box is the 68 base pair deletion of nucleotides 5656 to 5723 inclusive. The inserted box 
at the 3’ end of vpu represents the 5’ env open reading frame. (B) The deletion in vpu does not 
alter expression of p55gag or gp120env. Cell lysates were analyzed for HIV-1 protein expression 
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by Western blot analysis with anti-gp120env or anti-p24gag. (C) CEM-SS cells as in Figure 3.1 
were infected with LAI or LAI∆vpu at a multiplicity of infection of 0.05 and viral production 
was followed for 20 days with ELISA for p24gag. 
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Figure 3.2. Time courses of infection with wild type LAI and LAI∆vpu. (A) Longitudinal 
analyses of viral RNA in plasma of BLT mice infected with 3,000 TCIU of either LAI (gray 
solid line, filled circles, n=5) or LAI∆vpu (black dashed line, open triangles, n=3). Data 
represented as mean ±SEM. Light gray dotted line indicates limit of detection for viral RNA. (B)  
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Mean ±SEM of peak viral loads in copies of viral RNA per ml in plasma is reduced for 
LAI∆vpu: LAI, 4.83X106 ± 0.49X106 and LAI∆vpu 1.09X106 ± 0.15X106, Mann Whitney test, 
p=0.0357. Asterisk indicates p < 0.05. (C) Rank order of peak viral loads for mice in (A, B). 
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Figure 3.3. Infection with LAI∆vpu exhibits an attenuated pathogenic phenotype relative to LAI. 
BLT mice from Figure 5 were analyzed for loss of CD4+ T cells from peripheral blood. (A) The 
percentage of CD4+ T cells relative to pre-exposure levels in peripheral blood of BLT mice 
infected with either LAI (gray solid line, filled circles, n=5), LAI∆vpu (black dashed line, open 
triangles, n=3) or uninfected mice (light gray solid line, open squares, n=6) is presented. 
“%CD4+ T cells” fraction of CD4+ T cells out of total T cells with the pre-exposure level set to 
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100%. (B, C) BLT mice infected with 3000 TCIU of LAI (Figure 3.2) were sacrificed and 
analyzed for loss of CD4+ T cells and CD4+CD8+ thymocytes in tissues. (B) Flow cytometric 
analysis of cells from Bone Marrow, Spleen, Lymph Nodes, Liver and Lungs demonstrated 
decreases of the percentage of CD3+ T cells expressing CD4 after infection with LAI (medium 
gray bars, n=5) or LAI∆vpu (dark gray bars, n=3). Uninfected mice (light gray bars, n=10 except 
Lymph Node with n=5) are also presented. (C) Double positive (CD4+CD8+) thymocytes 
presented as percent of total thymocytes in human thymic organoid. LAI (medium gray bars, 
n=5) or LAI∆vpu (dark gray bars, n=3). Uninfected mice (light gray bars, n=6) are also 
presented. * < 0.05 
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CHAPTER 4: THE ROLE OF NEF IN THE CONTEXT OF JRCSF INFECTION, A CCR5 
TROPIC HIV-1 PRIMARY ISOLATE3 
4.1 Summary  
Background: The HIV-1 accessory protein Nef is critical for the development of AIDS. It has 
been shown that the highly pathogenic CXCR4-tropic virus LAI is rendered non-pathogenic in 
the absence of Nef and that LAI nef evolves to overcome a frame-shift to restore the nef open 
reading frame to regain partial Nef function, which ultimately leads to CD4+ T cell loss.  
Conversely, if irreparable deletions are incorporated into nef, this virus lacks the ability to 
deplete peripheral blood CD4+ T cells. It is not known, however, if Nef is needed for the 
depletion of CD4+ T cells during the infection of CCR5-tropic viruses. Here we used the CCR5 
tropic virus, HIV-1 JRCSF, to characterize the evolution of nef in vivo and the requirement of 
Nef for robust replication and depletion of CD4+ T cells.    
Results: I characterized the course of an intravenous infection with 90,000 TCIU of JRCSF  
 
3 Richard L Watkins, Nurjahan Begum, John L Foster and J Victor Garcia. The role of Nef in the 
context of JRCSF infection, a CCR5 tropic HIV-1 primary isolate. RW, NB, and JF performed 
experiments 
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(wild type) and compared this course of infection with that of viruses with defective nefs in BLT 
humanized mice: one with two large deletions in nef (JRCSFNefdd) and the other with a frame-
shifted nef (JRCSFNeffs).  JRCSF infection resulted in a 72.13% reduction in peripheral blood 
CD4+ T cells, while infection with JRCSFNefdd did not. In contrast, JRCSFNeffs eventually 
depleted CD4+ T cells, albeit at a much slower rate. We also tracked the evolution of nef 
throughout the course of infection of JRCSFNeffs.  JRCSFNeffs was replaced by virus with 
deletions in nef that restored the ORF.  A Nef representative of this in vivo nef evolution was 
determined through in vitro functional assays to lack the ability to downregulate CD4 but retain 
MHC1 downregulation.  
Conclusions: Like the highly pathogenic X4 tropic virus, LAI, JRCSF depends on Nef for 
optimal replication and pathogenicity. In addition, as seen for LAINeffs, the frame shift in 
JRCSF is repaired but the resultant protein has lost the required ability to downregulate CD4. 
However, unlike in the case of LAI, JRCSF Nef is needed for the T cell activation seen in wild 
type JRCSF infection.   
4.2 Introduction 
nef-defective HIV-1 has strongly attenuated viral replication and pathogenesis [62, 159-
161].  In addition, nef will evolve to overcome a four base insertion in codon 36 to restore its 
ORF, but in the process loses its ability to downregulate CD4. We now know that among the 
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many functions ascribed to Nef via in vitro investigation, its ability to downregulate surface 
expression of CD4 is responsible for nearly half of the CD4+ T cell depletion seen during HIV-1 
infection of BLT humanized mice [152].  Therefore, Nef’s overall impact on HIV-1 infection is 
due to its effect on CD4 downregulation activity and other Nef functions that together result in 
high viral loads and eventually the development of AIDS [60, 152]. 
To gain a better understanding of the function in vivo in the context of an R5 tropic HIV-
1 nef, we created a frame-shift in JRCSF nef (JRCSFNeffs) and used this virus to infect BLT 
humanized mice.  We followed the course of infection of this virus and compared it to wild type 
virus.  We specifically monitored viral replication and peripheral blood CD4+ T cell depletion 
and tracked the evolution of nef throughout the infection at two time points.  Because in the case 
of LAINeffs infection the ORF was restored rapidly, the reversion of JRCSFNeffs is also likely, 
making it difficult to determine the need for Nef to achieve high viral load and CD4+ T cell 
depletion. To assess Nef’s requirement for the maintenance of high viral loads and CD4+ T cell 
depletion we created irreparable deletions in the nef of JRCSF (JRCSFNefdd) and used this nef-
defective virus to infect BLT humanized mice. We then compared the course of infection with 
those of mice infected with JRCSF and JRCSFNeffs. The characterization of infection included 
1) CD4+ T cells in the blood, 2) plasma viral RNA levels, 3) and CD8+ T cell activation levels.      
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4.3 Experimental Procedure  
4.3.1 Preparation of BLT humanized mice  
 BLT humanized mice were prepared as described [60, 87, 185, 186, 191-198]. Briefly, 
thymus/liver implanted NOD/SCID IL-2γ-/- mice (The Jackson Laboratories, Bar Harbor, ME) 
were transplanted with autologous human CD34+ cells isolated from fetal liver (Advanced 
Bioscience Resources, Alameda, CA). Human reconstitution in the peripheral blood of these 
mice was monitored periodically by flow cytometry (FACSCanto; BD Biosciences). Mice were 
maintained at the Division of Laboratory Animal Medicine, University of North Carolina at 
Chapel Hill (UNC-CH) in accordance with protocols approved by the UNC-CH Institutional 
Animal Care and Use Committees.  
To ensure genetic diversity, seven different tissue donors were used to generate four 
groups of mice used for the experiments. All groups had at least two different human genetic 
backgrounds included in the evaluation of infection. JRCSFNeffs and JRCSFNefdd infected 
groups each shared a common donor with the JRCSF infected group. 
4.3.2 Cell lines and culture conditions  
 TZM-bl cells were maintained in Dulbecco's modified Eagle's medium (DMEM; Cellgro, 
Herndon, VA) and supplemented with 10% fetal bovine serum (FBS; Cellgro), 100 IU/ml of 
penicillin, 100 µg/ml streptomycin, and 2 mM glutamine (Cellgro) in 10% CO2 at 37°C.  
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Similarly, 293T cells were cultured under the same conditions as TZM-bl cells but in 5% CO2. 
The human CEM T cell line was cultured in RPMI 1640 medium supplemented with 10% fetal 
bovine serum (Hyclone), 50 IU of penicillin per ml, 50 µg streptomycin per ml, 2 mM L-
glutamine, and 1 mM sodium pyruvate in 10% CO2 at 37°C. 
4.3.3 Proviral clones 
 The proviral clone, pYK-JRCSF (accession # M38429), was described by Koyanagi et al. 
[260].  JRCSFNeffs was constructed to be defective for nef by digesting pYK-JRCSF with XhoI, 
filling in with Klenow and re-ligating, which, leaves the nef sequence intact but introduces a 
four-base frame-shift after nef codon 35. JRCSFNefdd was constructed by cutting with Xho1 and 
Acc65I, filling in with Klenow and religating. The junction retained the Xho1 site and was in 
frame.  The Xho1 site was then cut, filled, and ligated to create a frame shift. The 292 base 
deletion was made by site-directed mutagenesis.  
4.3.4 Virus production, exposure of BLT mice to HIV-1JRCSF and HIV-1JRCSF with mutated nefs, 
and flow cytometric analyses  
 Stocks of JRCSF, JRCSFNeffs, and JRCSFNefdd were prepared and titered as previously 
described [200, 201]. Briefly, proviral clones were transfected into 293T cells. Viral supernatant 
was collected 48 hours after transfection and diluted in DMEM, and supplemented with 10% 
fetal bovine serum, 100 IU penicillin/ml, 100 mg/ml streptomycin, and 2 mM glutamine. TZM-
 90 
bl cells were infected in 12-well tissue culture plates with 0.4 ml of virus at multiple dilutions in 
DMEM plus 10% fetal bovine serum containing DEAE dextran for 2 hours. Then, 1.0 ml of 
DMEM plus 10% fetal bovine serum was added and the plates were incubated overnight. Virus-
containing medium was removed the next day, replaced with fresh DMEM plus 10% fetal bovine 
serum, and the incubation continued for 24 hours. The cells were fixed with formaldehyde and 
glutaraldehyde and stained with 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (40 hours 
after first exposure to virus). Individual blue cells were counted directly to determine infectious 
units per ml (TCIU). Viral stocks were tittered in triplicate and at least two different titer 
determinations were performed for each virus preparation. 
BLT mice were exposed to infectious virus via tail vein injection with 90,000 TCIU. 
Viral load in peripheral blood of infected mice was monitored longitudinally by quantitative real-
time PCR using Taqman RNA to-CTTM 1-step kit from Applied Biosystems, USA [192, 193, 
202]. The sequences of the forward and reverse primers and the Taqman probe for PCR were 5’-
CATGTTTTCAGCATTATCAGAAGGA-3’, 5’-TGCTTGATGTCCCCCCACT-3’, and 5’-
FAM CCACCCCACAAGATTTAAACACCATGCTAA-Q-3’, respectively.  
CD4+ and CD8+ T cell levels were monitored by flow cytometric analysis as previously 
described [185, 196, 198]. Immunophenotyping was performed on blood samples collected 
longitudinally and on mononuclear cells isolated from tissues at harvest. Whole peripheral blood 
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(PB) from humanized mice was analyzed according to the BD Biosciences Lyse/Wash protocol 
(Cat. No. 349202), as previously described [203]. Briefly, following antibody labeling of whole 
blood, red blood cells were lysed. The remaining cells were washed and fixed and the sample 
was analyzed by flow cytometry. Tissue mononuclear cell isolations and immunophenotyping 
analyses were also performed according to published methods [185, 196, 198]. Flow cytometric 
gating for CD4 and CD8 cell surface expression was performed as follows: (step 1) forward and 
side scatter properties were used to set a live cell gate, (step 2) live cells were analyzed for 
expression of the human pan-leukocyte marker CD45, (step 3) human leukocytes were analyzed 
for hCD3, and (step 4) these T cells or thymocytes were analyzed for hCD4 and hCD8 
expression.  
The panel of antibodies for analysis of CD38+ and HLA-DR+ expression in CD8+ T cells 
was CD8 FITC (SK1), HLA-DR, PE (TU36) or IgG2bκ PE, CD4 PerCP (SK3), CD3 PE-Cy7 
(SK7), CD38 APC (HB7) or IgG1κ APC, and CD45 APC-Cy7 (2D1) (all purchased from BD 
Biosciences). Gating was performed as follows: (step 1) forward and side scatter properties were 
used to set a live cell gate, (step 2) live cells were analyzed for expression of the human pan-
leukocyte marker CD45, (step 3) human leukocytes were analyzed for CD3, (step 4) T cells were 
analyzed for CD4 and/or CD8 expression, (step 5) human CD8+ T cells were analyzed for HLA-
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DR and CD38 expression [186]. Gates defining HLA-DR and CD38 expression were set with 
isotype-matched flourophore-conjugated control antibodies.  
4.3.5 In vitro analysis of Nef activities  
 The in vivo selected 78 base-pair deletion was introduced into JRCSF nef and subcloned 
into the retroviral vector pLXSN [93]. CEM T cells were transduced to express JRCSFNef or 
JRCSFNeffsΔ-78.  Assays for CD4 downregulation and MHCI downregulation were described 
previously [93].  Nef expression was determined by Western blot analysis using anti-Nef AG11 
monoclonal antibody [93, 152, 205]. 
4.3.6 Sequence analysis of plasma virion RNA  
 Viral RNA was extracted from 20 µl of plasma from infected mice using the QIAamp 
Viral RNA Mini kit (Qiagen Sciences, USA). RNA was then reverse-transcribed into cDNA, 
which was then subjected to nested PCR. The outer primers for nef amplification are 5’-
AGCTTGCTCAATGCCACAGCC-3’ and 5’-GCTGCATATAAGCAGCTGCTTTTTG-3’. The 
inner primers are 5’-TAGAGCTATTCGCCACATACC-3’ and 5’-
GCTTGCTACAAGGGACTTTCCGC-3’. Gel purified PCR products were sequenced and 
aligned to HIVLAI sequences to determine if nucleotide changes had occurred. 
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4.3.7 Statistics  
 Mann-Whitney tests were performed in Prism version 5 (Graph Pad). All data were 
plotted as mean + S.E.M. 
4.4 Results 
4.4.1 Infection of BLT humanized mice with JRCSFNeffs  
 To characterize the infection of JRCSF with a defective nef, we generated an inactivating 
mutation by generating a frame-shift, in the manner previously described [152] (Figure 4.1). 
JRCSF and the nef frame-shifted JRCSF (JRCSFNeffs) were injected intravenously (iv, 90,000 
TCIU) into BLT mice (Figure 4.2). In Figure 4.2, wild type JRCSF-infected mice and negative 
control uninfected mice are compared to JRCSFNeffs-infected mice. JRCSFNeffs actively 
replicated, reaching a peak viral load of 3.83 + 2.82 x 106 (n=6), while JRCSF reached a peak 
viral load at 4.71 + 1.23 x 106 (n=6). The difference between the peak viral loads reached by 
these two viruses was not statistically different (p value=0.132, Mann Whitney). However, when 
early viral loads were compared a short delay in replication was observed for weeks 1 and 2 (p 
values= .0043 and .0075) (Figure 4.2 A).  These results suggest that whatever replicative 
advantage JRCSF has over JRCSFNeffs is transient.  
In mice infected with JRCSF, a continuous, slow decline in CD4+ T cells was observed 
with statistically significant differences compared to CD4+ T cell levels in uninfected mice from 
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weeks 2 through 14.  JRCSFNeffs did not reduce CD4+ T cells for 10 weeks; however, a sharp 
decline of 60.0% + 13.2% was observed at 14 weeks.  The difference was not statistically 
significant, but suggests that JRCSFNeffs had become capable of depleting CD4+ T cells.   
4.4.2 The in vivo evolution of nef leads to the reopening of the nef ORF 
  We sequenced nef from JRCSFNeffs viral RNA from blood from 8 and 14 weeks post-
infection (Figure 4.3 A).  At 8 weeks post-exposure, JRCSFNeffs nef sequence (designated “+4”) 
was present in only two mice.  nef sequences from the remaining four mice contained deletions 
ranging from 1 base to 105 bases. By 14 weeks post-exposure, JRCSFNeffs nef sequence could 
not be identified in any of the mice, suggesting that these nef mutants gave the viruses that 
express them an advantage in replication over JRCSFNeffs.  All nef mutants contained deletions 
that restored the nef ORF but did not result in wild type sequence.     
4.4.3 In vitro functional analysis of nef mutant that evolved in vivo obtained from enforced 
evolution  
 To assess in vitro phenotypes of ORF Nef in vivo generated in JRCSFNeffs infected 
mice, we chose JRCSFNeffsΔ-78, an in vivo generated nef that by 14 weeks replaced other nefs 
in this mouse.  The coding sequence was transferred into the retroviral expression plasmid, 
pLXSN, used to produce a retroviral vector that in turn was used to transduce CEM T cells [26]. 
 95 
CEM T cells expressing wild type and mutant Nefs were analyzed for Nef expression, CD4 
downregulation, and MHC Class I (MHCI) downregulation (Figure 4.3 C). NeffsΔ-78 was 
expressed at the same level as wild type Nef (Figure 4.3 B). Flow cytometric analysis of cell 
surface CD4 and MHC1 expression of CEM T cells transduced with JRCSF Nef showed 
downregulation of both proteins (Figure 4.3 C, [26, 93, 208]). NeffsΔ-78 was fully active for 
MHCI downregulation but completely devoid of CD4 downregulation activity.  
4.4.4 Infection of BLT humanized mice with JRCSFNefdd  
 Because JRCSFNeffs restores the nef ORF by week 14, leading to the loss of CD4+ T 
cells and wild type levels of replication, I characterized the course of infection of JRCSF with 
irreparable deletions in nef (Figure 4.4). We have demonstrated that LAI with two large deletions 
flanking the polypurine tract (LAINefdd) was indeed irreparable. We incorporated the same 
deletions into JRCSF nef (JRCSFNefdd) and used this virus to infect BLT humanized mice with 
90,000 TCIU (Figure 4.5). Mice infected with JRCSFNefdd (n=6) (Figure 4.5 A), like 
JRCSFNeffs (Figure 4.2 A), harbored active viral replication.  JRCSFNefdd reached a peak viral 
load of 2.29 + 1.67 x 106. This peak viremia was not significantly different from those of JRCSF 
or JRCSFNeffs infected mice. However, at weeks 1 and14 the viral loads of JRCSF and 
JRCSFNeffs infected mice differed: when compared to JRCSF, the JRCSFNefdd viral loads 
were statistically different at weeks 1 and 14 (p values= .0050 and .0260, Mann Whitney, 
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respectively) (Figure 4.2 A) and when compared to JRCSFNeffs, viral loads harbored by mice 
infected with JRCSFNefdd were also statistically different at week 12 and 14 (p value= .0152 
and .043). 
 We then compared CD4+ T cell levels in mice infected with JRCSFNefdd, JRCSF, or 
with JRCSFNeffs (Figures 4.2 B and 4.5 B). JRCSFNefdd infected mice did not differ from 
JRCSFNeffs in terms of CD4+ T cell levels throughout the course of infection. Similarly, CD4+ T 
cell levels throughout the course of infection did not differ statistically from uninfected mice at 
any point during the course of infection.  At week 4 and continuing to 14 wpi, JRCSFNefdd 
infected mice maintained higher levels of peripheral blood CD4+ T cells than mice infected with 
JRCSF (0.0043, 0.0043, 0.0043, 0.0022, 0.0022, and 0.0022, Mann Whitney, respectively).   
4.4.5 Nef is required for T cell activation during JRCSF infection  
 T cell activation has been associated with HIV-1 disease progression [261].  One 
explanation for the difference in the in vivo phenotypes of JRCSFNeffs and JRCSFNefdd would 
be an inability of these mutated HIV-1s to induce systemic T cell activation [211, 212]. One of 
the most commonly used indicators of T cell activation is the expression of both HLA DR and 
CD38 [262, 263]. When we compared the percent of CD8+ T cells expressing both HLA DR and 
CD38 in uninfected mice with the percent of CD8+ T cells expressing both HLA DR and CD38 
in JRCSF infected mice, we observed that the mice infected with JRCSF had a statistically 
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higher percentage of their CD8+ T cells that expressed both HLA DR and CD38, at 6, 8, and 12 
wpi (p values= .0095, .0422, and .0139, Mann Whitney, respectively). Mice infected with 
JRCSFNeffs or JRCSFNefdd did not differ statistically from uninfected mice nor from one 
another. When mice infected with JRCSF were compared to mice infected with JRCSFNeffs, 
statistically significant differences were observed at 6, 8, and 10 wpi.  We compared T cell 
activation in mice infected with JRCSF with mice infected with JRCSFNefdd. We observed that 
mice infected with JRCSFNefdd had lower percentages of CD8+ T cells expressing HLA DR and 
CD38 compared to mice infected with JRCSF at 6, 8, 10, and 12 wpi. Of interest is that no 
differences were seen between mice infected with JRCSFNefdd and mice infected with 
JRCSFNeffs.  A drop in HLA DR and CD38 is observed mice infected with either JRCSFNeffs 
or wild type JRCSF, which is currently unexplainable.  However longitutidal analysis of 
immunactivation conducted in sooty mangabeys demonstrate the extreme variability throughout 
out the course of SIV infection, this in addition to my data highlights our collective lack of 
understanding of the nuances of immune activation during viral infection [264].  Future 
experiments should be directed towards achieving better insight into the factors that influence 
chronic immune activation.    
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4.5 Discussion  
We have demonstrated that LAI depletes CD4+ T cells by 90% or more from the 
peripheral blood by 6 weeks post-infection [60, 152]. In this dissertation I show that JRCSF fails 
to deplete CD4+ T cells from the peripheral blood to this extent. At 6 weeks, LAI infection 
resulted in a 90% reduction. Conversely, JRCSF by 6 weeks resulted in only a 24% reduction in 
CD4+ T cells.  By 14 wpi, 27.9% + 5.9% of CD4+ T cells remained relative to the pre-infection 
level.   
We have shown that an CXCR4-tropic virus can correct a defective nef to regain partial 
function [152]; however,  it is unknown if this is true for nef in an CCR5-tropic virus. 
We established that the phenotypic differences between infection of BLT mice with wild type 
LAI and the nef-defective LAINefdd [60] are large and  demonstrated the ability of nef to evolve 
and restore partial functionality [152].  Viruses expressing Nef have a decisive replicative 
advantage over the frame-shifted LAINeffs and replace the nef-defective virus within a few 
weeks. Here we demonstrate that this is also the case in the context of the R5-tropic virus 
JRCSF. In this investigation we observe the restoration of the nef orf with a variety of deletions; 
however, these deletions take out a stretch of bases required for CD4 downregulation. In vitro 
analysis demonstrates that the Δ-78 Nef, like LAI Δ-1 and Δ-13, lacks the ability to downregulate 
CD4.  
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Because nef ORF is quickly restored in both JRCSFNeffs and LAINeffs infections, 
LAINefdd and JRCSFNefdd were used to assess the role of Nef in maintaining high viral loads 
and in the depletion of CD4+ T cells. Both the mice infected with JRCSFNefdd and with 
LAINefdd maintained their CD4+ T cells and had lower loads than their respective wild type 
controls.   I show that JRCSFNefdd infection does not induce CD8+ T cell activation, in contrast 
to LAINefdd infection, which induces CD8+ T cell activation to the same extent as infection with 
wild type JRCSF.  However, unlike Zou et al., I performed a longitudinal analysis of CD8+ T 
cell activation.  This difference in analyzing T cell activation may explain the difference between 
immune activation seen during LAINefdd and JRCSFNefdd infections.        
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Figure 4.1. A four base insertion creates a frame shift in nef.  Upper Panel, schematic 
representation of wild type JRCSF (WT JRCSF) is presented. Nucleotides 8784 to 9434 in NCBI 
accession number, M38429, represent the nef coding sequence. Lower Panel, A schematic of 
frame shifted nef (JRCSFNeffs) is presented. The insertion of GATC following nucleotide 8917 
is indicated. PPT, polypurine tract. 
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Figure 4.2. Viral load analysis and peripheral blood CD4+ T cell depletion in mice infected with 
JRCSFNeffs.  (A) Viral loads of BLT mice were plotted for BLT humanized mice exposed to 
90,000 TCIU of JRCSF (n = 6) and JRCSFNeffs (n = 6). Uninfected mice (n = 4) served as 
negative controls.  (B) The percent of CD4+ T cells out of total T cells in peripheral blood are 
plotted for mice in (A).  
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Figure 4.3. JRSCFNeffs restores its open reading frame.  (A) At two time points during the 14 
weeks of infection, plasma viral RNA was reverse transcribed, amplified by PCR, and nef 
sequenced.  By 8 weeks, virus RNA from all six mice had mutations in nef.  The original frame-
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shifted nef was present in only two mice.  By 14 weeks the original frame-shifted nef could no 
longer be identified by bulk sequencing. ? = additional sequences evident by bulk analysis (B) 
Nefs encoded by JRCSFNeffsΔ-78 and JRCSF were expressed in CEM cells. Western blot 
analysis confirmed the expression of the NeffsΔ-78 protein. (C) CEM cells expressing JRCSF 
Nef, JRCSF Neffs, and JRCSF NeffsΔ-78 were analyzed by flow cytometry for cell surface CD4 
and MHC Class 1 (MHC1) expression.  JRCSF NeffsΔ-78 was fully defective for CD4 
downregulation but functional for MHC1 downregulation.  Percentage of cells in each quadrant 
out of total cells is indicated.  
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Figure 4.4. Schematic of wild type JRCSF nef and JRCSFNefdd. Upper Panel, nef ORF Lower 
Panel, three bars represent nef coding sequence remaining in JRCSFNefdd. PPT: polypurine 
tract. In the lower bar the 5’ deletion incorporated into JRCSFNefdd is 115 nucleotides (8919–
9034). The 3′ gap in JRCSFNefdd is a frame-shift deletion of 292 bases (9115–9407).  
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Figure 4.5. Viral load and peripheral blood CD4+ T cell analysis in mice infected with 
JRCSFNefdd.  (A) Viral loads of BLT mice exposed to 90,000 TCIU of JRCSF (n = 6) and 
JRCSFNefdd (n = 6). Uninfected mice (n = 4) served as negative controls.  (B) The percent of 
CD4+ T cells out of total T cells in peripheral blood are plotted for mice in (A) Uninfected and 
wild type controls from Figure 4.2 are shown to facilitate comparison. 
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Figure 4.6. Infection with JRCSFNeffs and JRCSFNefdd do not induce T cell activation.  CD8+ 
T cell activation was measured longitudinally in peripheral blood prior to and after infection with 
90,000 TCIU of JRCSF (n=6), JRCSNeffs (n=6), or JRCSFNefdd (n=5). Activation is presented 
as percent of total CD8+ T cells in peripheral blood expressing both CD38 and HLA-DR.  
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 Nef-mediated downmodulation of CD4 is critical for wild type pathogenesis and replication 
Taking to account the findings of Zou et al., CD4 downregulation activity accounts for 
approximately half of Nef’s capacity to enhance viral replication and deplete CD4+ T cells and 
CD4+ CD8+ thymocytes, a result consistent with the high degree of conservation of the CD4 
downregulation activity of Nef [8].  The identity of Nef activities that account for the remainder 
of Nef’s effects is unknown. These yet to be identified activities present in LAINeffsΔ-1 and 
LAINeffsΔ-13 provide the virus a strong selective advantage over LAINeffs, which is fully 
defective for Nef expression.  In addition, wild type virus, expressing a fully active Nef, 
outcompetes virus expressing Nef that is specifically defective for CD4 downregulation (Figure 
2.2 A).  We also tested the Nef activities that depend on the SH3 domain binding site because the 
corresponding amino acid sequence in Nef is highly conserved.  However, the virus with nef 
mutated for SH3 domain binding (P72A/P75A) was essentially wild type in its ability to enhance 
viral replication and deplete CD4+ T cells and CD4+ CD8+ thymocytes.  
The current antivirals we have against HIV-1 are due to the intense research conducted 
on HIV-1.  When used in combination, antiviral drugs are effective at reducing both viral loads 
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and the speed of disease progression [265, 266].  The vast majority of these antivirals target the 
enzymatic activities of reverse transcriptase, protease, and integrase [267]. Taken together, these 
targets represent essential elements of viral replication.  HIV-1 mutates to gain back full or 
partial function of reverse transcriptase, protease, and integrase, which highlights the importance 
of identifying and designing therapies that target HIV-1 gene function as broadly as possible. 
A future direction of this research should be to understand the role that less studied 
functions of Nef play in CD4+ T cell depletion and viral replication.  Some of these functions 
include Nef-induced elevated release of exosomes or the role of Nef in inhibiting ASK1 [214, 
216].    
5.2 The loss of CD4 down modulation by Nef has a similar impact on HIV-1 infection as the loss 
of Vpu 
CD4 downregulation activity accounts for approximately half of Nef’s capacity to 
enhance viral replication and deplete CD4+ T cells and CD4+ CD8+ thymocytes; this dissertation 
concludes that the loss of Vpu has a similar effect on HIV-1 infection. This similarity raises the 
possibility that Nef and Vpu synergize to counter the capacity of CD4 to act as a major restrictor 
of viral replication.  In this regard, an interesting future direction would be to characterize the 
course of infection of a virus lacking both Nef-mediated CD4 downregulation and Vpu.  The 
combined effects of the absence of Nef-mediated CD4 downregulation and of Vpu can be 
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expected to yield a dramatic reduction in viral load and CD4+ T cell cytotoxicity. This hypothesis 
could be tested by combining the mutation generated by the enforced evolution of LAINeffs with 
LAIΔvpu (e.g., LAIΔvpuNeffsΔ-1) and monitoring viral loads and CD4+ T cell levels in 
LAIΔvpuNeffsΔ-1 infected mice.    
As mentioned in 5.1, novel antivirals that target Nef-mediated CD4 downmodulation, in 
combination with antivirals that disrupt less studied functions of Nef, could be effective at 
controlling HIV-1 infection. Conversely, another strategy for controlling HIV-1 infection could 
be combining antivirals that target Nef-mediated CD4 downregulation with antivirals that target 
Vpu.  Such an approach may be effective at drastically reducing CD4+ T cell cytotoxicity and 
viral replication during infection.    
5.3 Nef is required for T cell cytotoxicity and robust viral replication of the CCR5-tropic virus 
JRCSF.  
  Wei et al. demonstrated through use of the highly pathogenic CXCR4-tropic virus, LAI 
that Nef is required for the rapid depletion of CD4+ T cells and high viral loads in BLT 
humanized mice. CXCR4-tropic and CCR5-dual-tropic viruses appear in later stages of HIV-1 
infection in about 50% of patients and the appearance of dual-tropic viruses is associated with 
disease progression [268-270].  However, fully CXCR4-tropic viruses in the context of natural 
infections rarely occur [6].  The vast majority of natural infections are infections of CCR5-tropic 
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viruses [6].  I was therefore interested in assessing the requirement of Nef for high viral loads 
and CD4+ T cell depletion in the infection of the CCR5-tropic JRCSF.  I leveraged a nef 
defective JRCSF virus containing a frame shift in nef to infect BLT humanized mice.  During the 
course of infection the nef ORF was restored in all mice via a 1 base, a 78 base, a 4 base, or a 
105 base pair deletion.  The 78 base pair nef deletion was selected as a representative and was 
incorporated into a retroviral expression vector, which was then used to transduce CEM cells 
expressing both MHC1 and CD4. The Nef produced by the 78 base pair deleted nef was unable 
to downmodulate surface expression of CD4 but was fully functional for downmodulation of 
MHC1, which is an observation consistent with the data presented in Wei et al [60].  
 Due to the restoration of the nef ORF, the inactivation of nef through the genetic 
engineering of a frame shift is not sufficient for determining the necessity of a fully functional 
nef for high viral loads and CD4+ T cell loss during JRCSF infection.  We therefore leveraged 
another nef-defective JRCSF containing irreversible mutations in nef to determine the role of nef 
in CD4+ T cell cytotoxicity and reaching high viral loads during JRCSF infection in humanized 
mice.  These experiments demonstrate that Nef is required for both viral replication and CD4+ T 
cell loss in JRCSF infected BLT humanized mice.  I conclude in this thesis that as in the case 
with a CXCR4-tropic viral infection, the loss of CD4+ T cells and high viral loads during 
infection with a CCR5-tropic virus requires Nef.                
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5.4 Induction of immune activation by HIV-1 JRCSF depends on Nef.  
During the course of JRCSF virus infection, Nef is required for replication and CD4+ T 
cell depletion.  Pressure is also exerted on the virus with a frame-shifted nef to have an ORF.  In 
the case of JRCSFNeffs, a mutated nef was observed that produces a partially functional Nef, 
which specifically lacks CD4 downmodulation. These results are similar to those seen with HIV-
1 LAI, a CXCR4-tropic virus.  
In the natural infection of the sooty mangabey with SIV, infection does not lead to the 
depletion of CD4+ T cells despite chronic replication, which is in stark contrast to SIV infection 
in rhesus macaques and HIV-1 infection in humans [271].  HIV-1 infection in humans and SIV 
infection in rhesus macaques leads to an increase in immune activation, whereas SIV infection in 
the sooty mangabey does not induce immune activation [271].  It is suggested that this difference 
in immune activation underlies the pathogenic difference seen between pathogenic HIV-1 
infection in humans and SIV infected macaques and non-pathogenic infection observed in SIV 
infected sooty mangabeys [271].  Therefore in my investigation into the role of nef in the 
depletion of CD4+ T cells during the course of HIV infection in BLT humanized mice, the 
difference in the viral replication and CD4+ T cell depletion in mice infected with either 
JRCSFNefdd or JRCSF may be due to the difference in T cell activation seen during infection.  
To my knowledge the experiments described in this dissertation are the first of its kind in that it 
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assessed T cell activation throughout the course an infection, which is experimentally 
manipulated to be non-cytotoxic. The longitudinal analysis of T cell activation shown here 
demonstrates that JRCSF infected mice have higher levels of T cell activated than those infected 
with JRCSFNefdd. I conclude from this experiment that Nef is required for T cell activation, and 
that T cell activation may underlie the pathogenic differences seen between wild type JRCSF and 
nef-defective JRCSF infection in humanized mice.  The significance of this observation lays in 
the fact that in humans, activation set point early in infection determines the rate of disease 
progression [186, 263, 272].  Future experiments should be designed to determine the role that 
immune activation plays in viral replication and CD4+ T cell depletion.  
5.5 Nef and future applications of the BLT humanized mouse HIV/AIDS research  
A perfect model for the analysis of human disease does not exist.  Animal models have 
allowed researchers to explore aspects of human disease that involve multiple components of the 
in vivo system.  However, animal models mimic only some of the nuances of human diseases.  
The establishment of human-animal chimeras have allowed for more of the subtleties of human 
disease to be appreciated and studied. The development of humanized mice through the 
engraftment of human tissues and immune cells into immunodeficient mice has changed 
biomedical research forever.  Specifically, HIV research, because HIV doesn’t naturally infect 
the mouse, has been revolutionized.  Revolutionized because these mouse-human chimeras 
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possess necessary target cells required for sustaining an HIV infection.  Now, the feasibility of 
complicated investigations into the dynamics of HIV infection, prevention, transmission, and 
treatment are simply a matter of imagination.  I have described in this thesis the leveraging of the 
animal model the BLT humanized mouse to investigate the viral factors that influence replication 
and CD4+ T cell loss during HIV-1 infection.  I have demonstrated that both Vpu and Nef are 
critical determinants of rapid CD4+ T cell depletion and robust viral replication during HIV 
infection.  I have also shown that of the multiple functions of Nef, its ability to downmodulate 
cell surface expression of CD4 is responsible of nearly half of the in vivo phenotype of a wild 
type infection.  Of interest the Nef mutant defective for SH3 domain containing proteins binding 
is statistically indistinguishable from a wild type infection in regards to replication and CD4+ T 
cell cytotoxicity.      
The inability of Nef to bind to SH3 domain containing proteins was made possible via 
mutation to the PXXP motif of Nef.  This mutation also inhibits Nef-mediated downmodulation 
of MHC1. Dudek et al. have determined that BLT humanized mice are able to mount an active 
CD8+ T cell response. However, if BLT mice have an active CD8+ T cell response, how then is 
the replication of the PXXP motif mutant nef HIV unable to be controlled?  An explanation 
could be that CD8+ T cell response is in most individuals is incapable of halting HIV-1 infection 
even in the absence of Nef mediated downmodulation of MHC1.  Some individuals are capable 
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of spontaneously controlling HIV-1 infection in the absence of treatment.  Certain HLA’s have 
been associated with control of viremia.  HLA-B*57, specifically, has been associated with the 
ability to control viremia in the absence of treatment.  Dudek et al. demonstrated that humanized 
BLT mice can be engineered to express HLA-B*57, and demonstrated that animals expressing 
the protective HLA-B*57 allele showed enhanced control of viral replication [87].  Achieving an 
understanding of the host and viral factors that contribute to the controller phenotype may aid in 
the identification of new therapies.  Protective HLA alleles represent one of the host factors 
influencing the controller phenotype, however the viral factor influencing control of viremia 
could be Nef.  Dyer et al. explores this in their investigation into a group of elite controllers and 
long term nonprogressors. Dyer and colleagues followed a group of five long-term non-
progressors over the course of 25 years, and it was observed that protective HLA alleles were 
overrepresented in these five individuals in regards to these alleles frequency in the general 
population. Of these five, three were considered to be elite controllers. These three individuals 
are from the Sydney Blood Bank Cohort, a group of individuals receiving a blood transfusion 
contaminated with a nef defective virus (Table 5.1) [273]. 
I have helped establish the BLT humanized mouse as a model to explore the dynamics of 
Nef-influenced CD4 depletion and viral replication.  I propose that we leverage this model to 
investigate the how Nef and certain HLA alleles determine the elite controller phenotype. The 
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genotyping of donor tissues will allow for the identification of known protective HLA alleles, 
specifically but not limited to HLA-B*57, HLA-B*27, and HLA-B*44.  Once identified, donor 
tissues expressing protective HLA alleles can be used to generate BLT humanized mice similar 
to Dudek et al.  These protective HLA expressing animals can then be exposed to wildtype HIV 
or exposed to a nef-defective HIV.  I hypothesize that in the absence of Nef, mice that possess a 
protective HLA allele will be capable of controlling infection.  Elite controllers are able to 
suppress viremia to under 100 copies of viral RNA per mL of plasma, and it will interesting to 
see if mice expressing protective HLA alleles are able to suppress the viremia of a nef-defective 
virus to a level that can be deemed elite controller status [274].  Dudek et al. observed escape 
mutations with a high level of reproducibility within nef and env, which he described as being 
one of the major advantages of the BLT humanized mouse model. However, these escape 
mutations were associated with reduced viral replication.  In the future experiments that I 
propose, the monitoring of gag, env, and nef sequences for escape mutations be included.  In the 
absence of Nef-mediated downmodulation of MHC1, escape mutations should be readily 
observed, and can be correlated to reduced viral loads.   
In summary I have shown that the BLT humanized mouse model has tremendous utility, 
and can be leveraged towards discerning the factors that influence many aspects of HIV infection 
and disease progression.  Specifically in determining the viral factors that influence viral 
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replication and T cell cytotoxicity, two of the most fundamental nuances of the progression to 
AIDS during HIV infection.  In addition I have also demonstrated that the humanized mouse can 
be used in assessing what host factors influence disease progression, namely, immune activation, 
which here within this thesis represents the first investigation of its kind in which the 
pathogenesis of an HIV-1 infection can be intentionally manipulated through the ablation of the 
accessory protein Nef.  The future of Nef and the BLT humanized mouse may hold the answer as 
to how some individuals are able to avoid progression to AIDS through self-suppression of HIV-
1 viremia in the complete absence of therapy.                        
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TABLE 5.1: Long-term non-progressors followed in Dyer et al. (from Dyer et al. 2008) 
Current 
Long-term non-progressors: 
Study Subject ID  Years HIV+  ART Status  Δnef  HLA 
C49‡  23.6  naive  Δnef 
A 2,11 
B 7,60 
C64‡  24.7  naive  Δnef 
A 2,32 
B 7,44 
C135‡  26.9  naive  Δnef 
A 1,33 
B 50,57 
C13  23.2  naive  wt 
A 3,25 
B 18,27 
C53  23.4  naive  wt 
A 2,24 
B 15,40 
‡ Sydney blood bank cohort 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